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Silybum marianum L. Gaertn. (commonly referred to as milk thistle) is a weed 
that has been used medicinally for over 2000 years. The therapeutic qualities 
of milk thistle are due to the presence of the flavonolignan silymarin.  
 
Herbal medicine is becoming increasingly popular in South Africa and, 
according to the WHO, an estimated the 80% of the global population rely on 
these medicines for primary health care. Due to the large number of 
constituents in herbal medicines, various differences between individual plants 
occur as a result of their agricultural history. However, few of the herbal 
medicines available to the consumer have been evaluated by the South African 
Health Products Regulatory Authority (SAHPRA). As such, some of these 
herbal medicines may therefore have questionable quality standards. A study 
conducted in 2019 on the chemical and microbiological quality of 26 milk thistle 
products sold in America and Czech Republic, noted large differences in the 
observed silymarin and declared silymarin and high concentrations of several 
pesticides, as well as the presence of microbiological contamination. No 
studies have yet been done comparing the quality of milk thistle products in 
South Africa. 
 
The aim of this study was to assess the presence of flavonolignans, elemental 
impurities and pesticide residues in various Silybum marianum L. Gaertn. 
products available in South Africa through the use of liquid chromatography-
mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-
MS) and inductively coupled plasma-mass spectrometry (ICP-MS). 
 
Six different brands of commercial Silybum marianum L. Gaertn. herbal 
capsules were procured from various pharmacies and health stores around 
South Africa. Samples were removed from the packaging and separated into 
individual batches and then randomly labelled (in order to ensure anonymity 
iv 
 
and eliminate bias). The samples underwent analyses using LC-MS for the 
presence of flavonolignans, GC-MS for pesticide residues, and ICP-MS for 
heavy metals and trace elements.  
 
To determine the quality of the products, the results of the chromatographic 
fingerprint analysis, silymarin content, pesticide residues, heavy metal and 
trace element impurities, mass of capsule contents and value for money for 
each of the samples were compared and the following results were obtained. 
All samples were observed to have the correct chromatographic peaks as 
associated with the presence of silymarin, however the silymarin 
concentrations detected were 68,65- 78,62% below the declared silymarin 
content on their labels. No pesticide residues were detected in any of the 
samples. Concentrations above permissible limits set by the WHO were 
observed for toxic elements lead (0,5 ug/g), nickel (2,0 ug/g) and cadmium (0,5 
ug/g) in four samples.  Most of the masses of the capsule contents (silymarin 
and milk thistle powder) were much greater than declared by product labels, 
excluding one product which was below the declared mass.  
 
In conclusion, the results of this present study strongly indicate the need for 
strict controls of the composition and chemical contaminants of commercial 
milk thistle extracts by both manufacturers and regulatory authorities. The 
inaccurate declarations of these products as well as contamination by toxic and 
biologically active elements may account for the inconsistency seen in the 
results of clinical trials but could also be responsible for possible adverse health 
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1.1  Problem Statement 
Silybum marianum L. Gaertn. (syn. Carduus marianus L., and commonly 
referred to as Silybum marianum) also known as milk thistle, has been utilized 
as a herbal medicine for over 2000 years and is still regularly used, grossing 
16,8 million US dollars in the USA in 2015 (Andrew & Izzo, 2017). It is today 
the most popular herbal product used for the treatment of chronic liver disease 
(Freedman et al., 2011). The therapeutic qualities of milk thistle are due to the 
presence of the main active constituent silymarin (Karkanis et al., 2011).  
 
Herbal medicine is becoming increasingly popular in South Africa (Okem et al., 
2014), however few of the herbal medicines available to the consumer have 
been evaluated by the South African Health Products Regulatory Authority 
(SAHPRA), previously known as the Medicine Control Council (MCC). As such, 
some of these herbal medicines may therefore have questionable quality 
standards.  
 
Due to the large number of constituents in herbal medicines, various 
differences between these plants occur as a result of their agricultural history 
including their growing, harvest, drying and storage. A study by Fenclova et al. 
(2019) on the chemical and microbiological quality of 26 milk thistle products 
sold in America and Czech Republic, noted large differences in the observed 
silymarin and declared silymarin, great numbers and high concentrations of 
mycotoxins and several pesticides as well as the presence of microbiological 
contamination. No studies have yet been done comparing the quality of milk 




1.2  Aim 
The aim of this study is to assess the presence (detected levels and the 
comparison to declared levels) of flavonolignans, elemental impurities and 
pesticide residues in various Silybum marianum L. Gaertn. (milk thistle) 
products available in South Africa through the use of liquid chromatography-
mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-
MS) and inductively coupled plasma-mass spectrometry (ICP-MS). 
 
1.3  Importance of the Study 
An increase in the use of medicinal plants has been seen in developed 
countries in recent years, this is partly due to the common misperception that 
because the product is natural that it is safe and harmless (Ababneh, 2017; 
Dghaim et al., 2015). However, with the exceptional growth in the market, the 
safety of these herbal products has become of increasing concern (Brinker, 
2014; Kosalec et al., 2009). Good manufacturing practices (GMP) are 
guidelines laid out by regulatory and licensing authorities that aim to ensure 
consistent, controlled and quality products. GMP is vital if quality herbal 
medicines are desired (WHO, 2011). The most common areas where GMP is 
compromised is (i) through misidentifying the starting plant material; (ii) through 
the adulteration of the herbal medicine with other pharmaceuticals; (iii) with 
substitution of the plant matter with either a subspecies or the incorrect plant 
part; and (iv) in contamination with pesticides, microbes or heavy metals such 
as nickel, lithium, strontium and arsenic (Karimi et al, 2011). The analysis of 
the presence of flavonolignans, elemental impurities and pesticide residues in 
various Silybum marianum through the use of LC-MS, GC-MS and ICP-MS will 
therefore demonstrate their quality. 
 
1.4  Expected Outcomes 
The results of the testing may determine whether flavonolignan levels meet 
label statements and assess for the presence of contamination, heavy metals 
3 
 
or substitutions within the herbal extracts. The results of this study have been 
reported to SAHPRA and therefore, influence quality checks. This study will 
provide insight into the quality control of milk thistle products available in the 






























The use of medicinal plants has been integrated into all systems of traditional 
medicine. It is often the primary source of healthcare in developing countries 
(Kosalec et al., 2009). The World Health Organization (WHO) estimates that 
65%- 80% of the world population depend primarily on plant-derived medicines 
for health care (Annan et al., 2013; Dghaim et al., 2015; Shaban et al., 2016). 
Herbal products are the dominant source of therapy in Africa (Okem et al., 
2014) and the United States is estimated to spend more than $30 billion 
annually on complementary and alternative medicines (Abdulla et al., 2019).  
 
2.1  Milk Thistle 
Silybum marianum L. Gaertn. (syn. Carduus marianus L., and often referred to 
as Silybum marianum) also known as milk thistle, has been utilized as a herbal 
medicine for over 2000 years and is still regularly used, grossing 16,8 million 
US dollars in the USA in 2015 (Andrew & Izzo, 2017). It is today the most 
popular herbal product used for the treatment of chronic liver disease 
(Freedman et al., 2011). The therapeutic qualities of milk thistle are due to the 
presence of the active constituent silymarin (Karkanis et al., 2011). 
 
2.1.1 Milk Thistle Plant 
Milk thistle is a medicinal plant originating from the Mediterranean (Siegel & 
Stebbing, 2013) and is a member of Asteraceae or Compositae family (Lucini 
et al., 2016) as seen in Table 2.1. 
 
The tap-rooted annual or biennial plant evolves from large rosettes of green, 
obovate, glabrous leaves with white veins and spiny margins (Karkanis et al., 
2011). It has an erect stem which can grow up to 2 m tall (Gresta et al., 2007). 
Each stem ends in a hemaphrodite flower head of red-purple tubular florets 
5 
 
resembling thistles (WHO, 2004). The inflorescences are 2,5- 5 cm in diameter 
and are encircled by spiny bracts (Karkanis et al., 2011). As seen in Figure 2.1, 
each flower head produces up to 190 seeds or fruits as the plant completes its 
annual or biennial life (Gresta et al., 2007; Karkanis et al., 2011). The seeds (5- 
8 mm long) are hard-coated, black or brown achenes with a long, silvery-white 
pappus (CABI, 2020). Within the ripe seed, the active constituent silymarin can 
be found (WHO, 2004).  
 
Table 2.1: Taxonomic Hierarchy of Silybum marianum (L.) Gaertn (Sabir et 
al., 2014) 
 












Species Silybum marianum (L.) Gaertn. 
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2.1.2 History of Use and Naming of Milk Thistle 
The use of medicinal plants is possibly the oldest means of treating disease 
(Kosalec et al., 2009). Milk thistle has been cultivated for over two centuries as 
a medicinal plant for the treatment of various disorders such as liver and 
gallbladder disease, snake bites, insect stings and mushroom poisoning 
(Karimi et al., 2011). The first person to describe the plant was Theophrastus, 
a Greek philosopher in the 4th century B.C. and he termed it “pternix” (Zonoubi 
et al., 2019). Plinus the elder, a Roman author and natural philosopher in the 
1st century A.D., suggested a formula of milk thistle juice extract with fruits and 
honey (Ross, 2008) for “carrying off bile” (Zonoubi et al., 2019).  The genus title 
“silybum” was given to many edible thistles by Pedanius Dioscorides the Greek 
physician, who went on to describe the use of milk thistle for snake bites in his 
materia medica in the 1st century A.D. (Karkanis et al., 2011; Zonoubi et al., 
2019). According to folklore, its distinctive white-veined leaves and milky-white 
sap came from a single drop of the Virgin Mary's milk (Siegel & Stebbing, 2013), 
therefore the name “marianum” was given to the specific species. The plant 
was customarily utilized as a galacatogogue, to promote the flow of breast milk, 
perhaps lending to the name milk thistle (Ross, 2008).  
 
In the 16th century, British botanist John Gerard recommended milk thistle for 
the treatment of melancholic disease (Siegel & Stebbing, 2013), and Nicholas 
Culpeper for jaundice and affinities of gall (Culpeper, 2018). During the humoral 
era of medicine, Culpeper believed milk thistle to have the energetics of a dry, 
hot temperament, corresponding to the choler humor and belonging to Mars 
under the fire sign of Aries (Boh & Breakspear, 2015; Culpeper ,2018).  
 
In the 1970’s Johannes Gottfried Rademacher, a German scientist and 
physician, developed a tincture or ethanol extract of milk thistle seeds and 
prescribed it for liver ailments (Lee & Liu, 2005). This gained the interest of 
other scientists in Germany at the University of Munich (Vania, 2012) and soon 
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milk thistle was approved by the German Commission E Monograph (Hudson, 
2012).  
 
2.1.3 Active Constituents of Milk Thistle 
The therapeutic qualities of milk thistle are due to the presence of the active 
constituent silymarin (Karkanis et al., 2011). Silymarin is found in the seed of 
the plant (Siegel & Stebbing, 2013) and is a complex mixture of 65- 80% 
flavonolignans (Albassam et al., 2011), comprising of silybin A and B, isosilybin 
A and B, isosilychristin, silydianin and silychristin and flavonoid taxifolin (Sabir 
et al., 2014). This mixture is made up of 20- 40% silychristin and silydianin, 40- 
65% is silybin A and silybin B and 10- 20% is isosilybin A and isosilybin B 
(Csupor et al., 2016). Silybin, silydianin and silychristin occur as positional 
isomers, while silybin A and B and isosilybin A and B are diastereomers (Poppe 
& Petersen, 2016). Other flavonolignans present in milk thistle include 
dehydrosilybin, deoxysilydianin, deoxysilycistin, silybinome, silandrin, 
neosilyhermin and silyhermin (Sabir et al., 2014). Biogenetically flavonolignans 
are the result of the oxidative coupling between two phenylpropanoid units of 
coniferyl alcohol and a flavonoid, as seen in Figure 2.2 (AbouZid et al., 2017). 
Flavonolignans were first identified in milk thistle seeds and are characteristic 




Figure 2.2: Biosynthetic pathways for Silybum marianum flavonolignans 
(AbouZid et al., 2017). 
 
2.1.4 Medicinal Use and Applications of Milk Thistle 
According to the WHO, it is estimated 80% of the global population rely on the 
use of herbal medicines for primary health care (Shaban et al., 2016). Milk 
thistle is a commonly purchased herbal medicine used for a variety of 
established health benefits (Albassam et al., 2011). The primary extract of milk 
thistle is silymarin, a mixture of flavonolignans of known therapeutic activity. 
Research has shown Silybum marianum to have anti-oxidant, anti-
inflammatory, hepatoprotective and antifibrotic properties, as well as the ability 
to chelate iron (Boh & Breakspear, 2015; EMA, 2013). Milk thistle has also been 
shown to have cardioprotective and anti-tumour properties while having 
minimal adverse effects or drug interactions (Tamayo & Diamond, 2007). There 
is currently intense research being done on its use in the clinical therapy of 
cancer for chemoprevention, treatment, and amelioration of chemotherapy-
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associated side effects (Csupor et al., 2016; Karimi et al., 2011; Sabir et al., 
2014). 
 
The main action of milk thistle is hepatoprotective, promoting hepatocyte 
regeneration and decreasing cholesterol levels (Lucini et al., 2016; Vania, 
2012). Due to its steroid structure, silymarin increases hepatocyte regeneration 
by enhancing DNA and RNA synthesis (Karimi et al., 2011) and the active 
constituent silybin has been seen to stimulate macromolecular biosynthesis by 
increasing the rate of ribosomal RNA synthesis both in vitro and in vivo (WHO, 
2004). Milk thistle extracts have been reported to promote hepatic regeneration 
in partially hepatectomized rat livers (Abenavoli et al., 2018; Sonnenbichler et 
al., 1986; WHO, 2004) and been proven to be highly effective for the treatment 
of alcoholic liver cirrhosis (Sabir et al., 2014).  It has also been prescribed in 
the German Commission E Monograph for the treatment of cirrhosis and 
hepatotoxicity (Siegel & Stebbing, 2013). 
 
Silymarin alters the structure of the external membrane of the hepatocytes and 
regulates its permeability (Karimi et al., 2011). The liver is where most toxins 
are metabolized in the body and therefore, stabilizing the membrane protects 
the liver from hepatotoxicity by preventing foreign bacteria from entering the 
cell through the enterohepatic circulation (Boh & Breakspear, 2015). Silymarin 
has antihepatotoxic properties against a large variety of toxins, especially that 
of the Amanita phalloides (death cap mushroom) (Karimi et al., 2011; Siegel & 
Stebbing, 2013; Wren & Williamson,1988) where fatality rates have been seen 
to drop from 30-40% to 0% in patients receiving silymarin injections daily 
(Lacombe & St-Onge, 2016; Vania, 2012). This is because it prevents the 
amatoxin from entering the hepatocyte (Sabir et al., 2014), and therefore avoids 
fatal haemorrhagic necrosis of the liver (Boh & Breakspear, 2015). Silybin is 
also shown to be protective against hepatotoxins such as acetaminophen, 




A recent meta-analysis of eight randomized controlled trials concluded that 
silymarin had improved the liver function of patients diagnosed with non-
alcoholic fatty liver disease through the reduction of their transaminase levels 
(Zhong et al., 2017). This research received a rating of Level 1 of evidence, 
indicating its high quality (Abenavoli et al., 2018).  
 
The anti-oxidant properties of silymarin are due to its ability to scavenge free 
radicals and increase the cellular concentration of glutathione (Hudson, 2012; 
Karimi et al., 2011). This inhibits lipid perioxidation and reduces excessive 
reactive oxygen species (ROS) and therefore decreases cellular damage (Boh 
& Breakspear, 2015; Karimi et al., 2011). Most patients who undergo cancer 
treatment are prone to excessive ROS, oxidative stress, reduced glutathione 
and lipid perioxidation, thus milk thistle is often useful in these patients (Karimi 
et al., 2011; Tamayo & Diamond, 2007).  
 
2.2  South African Regulation of Herbal Medicines 
In 2013, the South African Minister of Health made revisions to the Medicines 
and Related Substance Act of 1965 which classifies all medications into 
individual categories and brought Category D into existence. Under this act 
complementary medicines were defined to Category D and required to register 
with the South African Health Products Regulatory Authority (SAHPRA), 
previously the Medicines Control Council (MCC) (SAHPRA, 2020a; SAHPRA, 
2020b). In 2017, Category D was further subcategorised into discipline-specific 
complementary medicines and health supplements. Medicines falling under the 
discipline-specific divisions originate from Aromatherapy, Ayurveda, 
Homeopathy, Traditional Chinese Medicine, Unani Tibb and Western Herbal 




All complementary medicines have the right to sale in South Africa provided 
that a license has been issued to the manufacturers, importers, exporters, and 
wholesalers or distributors of the product by SAHPRA. These products are 
encouraged to be of low risk and therefore may not claim any therapeutic effect 
and are not subjected to the same level of legal and manufacturing scrutiny 
(Kim et al., 2013; SAHPRA, 2019).  
 
2.3  Quality of Herbal Medicine 
Medicinal plants are intrinsically complex and all have many constituents, 
therefore allowing for many variations which can occur as a result of either the 
growth, harvest, drying or storage of the plant matter used (Bauer, 1998; Ndolo, 
2018). The most common areas for product safety to be compromised come 
from: (i) adulteration with undeclared potent pharmaceutical substances; (ii) 
misidentification or substitution with noxious plant species; (iii) and the use of 
materials contaminated with harmful microbes, heavy metals, radioactive 
substances or agricultural chemical residues (Kosalec et al., 2009).  
 
An increase in the use of medicinal plants has been seen in developed 
countries in recent years, this is partly due to the common misperception that 
because the product is natural that it is safe and harmless (Ababneh, 2017; 
Dghaim et al., 2015). However, with the exceptional growth in the market, the 
safety of these herbal products has become of increasing concern (Brinker, 
2014; Kosalec et al., 2009). Herbal medicines are readily available over the 
counter for self-medication and therefore more likely to be subject to 
uncontrolled use or misuse (Perez-Parada et al., 2011). 
 
In order to ensure consistent quality, SAHPRA requires agricultural production 
data which should include information about the seed selection, cultivation and 
harvesting conditions, and the expression and distillation of the herb according 
to their version of Good Agricultural and Collection Practices (GACP) and Good 
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Laboratory Practice (GLP) guidelines. Good Manufacturing Practice (GMP) 
guidelines requiring the standardisation of the manufacturing process, 
premises and documentation as well as regular quality control checks are also 
mandatory (SAHPRA, 2020b).  
 
2.3.1 Good Agricultural and Collection Practices of Medicinal Plants 
Producing herbal products consistent in quality begins by establishing GACP 
for starting materials with the main aims being consumer safety and 
environmental sustainability. In order to be compliant with existing guidelines 
producers, traders and processors of medicinal plants must implement a quality 
assurance system for the seed selection, collection, cultivation and harvesting 
conditions (EMA, 2006). 
  
2.3.1.1 Good Agricultural Practices of Medicinal Plants 
Good Agricultural Practices (GAP) begins with the selection of the medicinal 
plant to be cultivated (EMA, 2006). The plant should belong to the species as 
dictated by the relevant pharmacopoeia or regulatory authority, and should be 
botanically identified according to its scientific and common English names 
(Ndolo, 2018). The seeds should be selected from reputable suppliers who can 
provide evidence of the identity, quality, performance and breeding history of 
the plant. All materials used in the plant propagation should be certified as 
organic and should remain free of microbial contamination (Zhang et al., 2011). 
Conservation Agriculture (CA) techniques should be followed during cultivation 
with the aim of conserving, improving and more sustainably utilizing natural 
resources.  The region of growth and environmental conditions must be optimal 
for the specific medicinal plant as many plants derived from the same species 
when cultivated at different sites, have shown substantial differences in quality 
due to the influence of soil, climate, irrigation and drainage. Contact with soil 
should be avoided and pesticide and insecticide use should be kept to a 
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minimum. Plant maintenance and protection must be performed by qualified 
personnel (WHO, 2003).  
 
2.3.1.2 Good Collection Practices of Medicinal Plants 
Personnel with knowledge of good collecting techniques, operation of 
equipment, handling of plant matter as well as cleaning, drying, storage and 
transport should be assembled. All personnel should (i) have sufficient 
knowledge and training pertaining to the relevant plant; (ii) have good personal 
hygiene and (iii) wear appropriate protective clothing. Harvesting should be 
done during the optimal season for the specific plant and any equipment used 
should be cleaned in order to lessen contamination (WHO,2003). Botanical and 
taxonomic verification of the plant material as specified by the pharmacopoeia 
must be performed by personnel before collection and the details should be 
documented (Ndolo, 2018). Collection techniques aim to conserve natural 
populations and their associated habitats, and this is done through maintaining 
a healthy population density of the medicinal plant, encouraging its 
regeneration and not placing the species at risk (EMA, 2006). Both the social 
and ecological impacts of cultivation on the site should be investigated and 
monitored. Medicinal plants may be collected in the wild, however, it is not 
recommended (WHO, 2003).  
 
It is important that the correct plant part is collected and that it is collected in 
the prescribed season at the correct phase of plant development. Levels of 
active constituents vary with the different phases of plant development (Poppe 
& Petersen, 2016). Efforts should be made to minimize the risk of 
contamination and plant material should be collected in clean vessels from 





2.3.2 Good Manufacturing Practices 
GMP are quality assurance guidelines laid out by regulatory and licensing 
authorities that aim to ensure consistent, controlled and quality products. GMP 
is vital if quality herbal medicines are desired (Dhami & Mishra, 2015; WHO, 
2011). The most common areas where GMP is compromised are: (i) through 
misidentifying the starting plant material; (ii) through the adulteration of the 
herbal medicine with other pharmaceuticals; (iii) with substitution of the plant 
matter with either a subspecies or the incorrect plant part; and (iv) in 
contamination with pesticides, microbes or heavy metals such as nickel, 
lithium, strontium and arsenic (Karimi et al., 2011). 
 
An efficient GMP system begins with having enough personnel at every stage 
with the relevant knowledge, training, and qualifications (Ndolo, 2018). 
Personnel should clearly understand all their responsibilities as well as 
maintain a high standard of personal hygiene. Detailed hygiene procedures 
should be laid out to all personnel and protective uniforms should be issued. 
Personnel should never directly touch any materials with their bare hands 
(SAHPRA, 2020b) 
 
The premises and equipment should be designed and adapted to best suit its 
intended operations allowing for effective cleaning, production and decreased 
risk of contamination (Kosalec et al., 2009). The manufacturing zones should 
be well controlled and kept free from food, drink or other items that may 
negatively affect the quality of the products (SAHPRA, 2020b). 
 
It is important to have an objective observer responsible solely for quality 
assurance (Ndolo, 2018). A quality control department with its own supervisor 
and laboratories should be formed or outsourced. At these laboratories 
analytical testing of the starting material, intermediate and complete products 
as well as packaging may take place. Samples of every complete batch and 
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related documents must be kept and stored for a minimum of 12 months after 
the date of expiration. Extensive documentation of every step of the 
manufacturing process should be kept up to date and free from errors (WHO, 
2011).  
 
2.3.3 Quality Issues Related to Milk Thistle 
2.3.3.1 Inconsistent Levels of Active Constituents 
To ensure and demonstrate the quality of a milk thistle extract, its quantitative 
chemical profile of bioactive compounds must be determined (Dhami & Mishra, 
2015). The bioactive compounds present in milk thistle are classified as 
constituents with known therapeutic activity. These constituents act as 
analytical markers in a chromatographic fingerprint for identification and 
quantification (EMA, 2008).  
 
It has been seen that distinct chemotypic variations of milk thistle result from 
different environmental conditions and genotypes (Karkanis et al., 2011). 
Variations in chemotypes produce variations in the relative amounts of the 
several flavonolignans present in silymarin (Poppe & Petersen, 2016), and this 
results in inconsistencies in the therapeutic efficacy of the product (Dhami & 
Mishra, 2015). Lucini et al., (2016) found that different genotypes of milk thistle 
not only create differences in the present bioactive compounds, but they also 
cause differences in anti-oxidant activity.  
 
For a product to have consistent and reproducible quality, the constituent 
content must be reported in an expected range (EMA, 2006).  
 
A study completed in America in 2016 found that eight out of ten milk thistle 
products tested did not contain as much silymarin as expected with many 
products not meeting the standard minimum quantity (ConsumerLab.com, 
2016). The majority of these milk thistle supplements are said to be 
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standardised to contain 70%- 80% silymarin (Abenavoli et al., 2018; Lee et al., 
2007) however, according to this report they were found to contain on average 
between 48% and 67%. The reason for this is because many products are 
tested with UV spectrophotometric analysis which provides an inaccurately 
increased result as this method is not specific to milk thistle and identifies other 
compounds as silymarin. Products tested with improved methodology and 
quantification with highly sensitive equipment, such as liquid chromatography, 
yields more accurate results, but are usually more expensive (McCurdy, 2016).  
 
2.3.3.2 Extraction and Processing Residues 
Milk thistle is sometimes contaminated with gasoline as a result of cheap 
industrial processing. Hexane can also be found in milk thistle products as it is 
a cheap solvent often used in the extraction of active constituents. 
Enhancements to Silybum marianum L. Gaertn.is done with Schisandra 
chinensis (Turcz.) Baill, Cynara scolymus (L.) and Taraxacum officinale (L.) 
which influence the amount of flavonolignan (Mudge et al., 2015). 
 
2.3.3.3 Pesticide Residues 
Pesticides are chemical compounds intentionally released into the environment 
to control, repel, prevent and eradicate pests (Kosalec et al., 2009; Zikankuba 
et al., 2019). The use of pesticides increases agricultural productivity, crop yield 
and protection, affordable food as well as the farmers’ income (Zikankuba et 
al., 2019). Medicinal plants are considered valuable crops, therefore farmers 
are inclined to protect them and prevent possible economic losses (Chen et al., 
2016). Milk thistle is susceptible to many insects, pests and disease (Csupor et 
al., 2016). Pesticides that may be relied upon for protection of milk thistle crops 
include insecticides, rodenticides, herbicides and fungicides (Zhang et al, 
2011) and are categorised according to chemical structure, toxicity and mode 
of action (Kosalec et al., 2009; Zikankuba et al., 2019). They are grouped as 
organochlorine pesticides (OCPs), organophosphorus pesticides (OPs), 
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nitrogen-containing pesticides and organic pesticides (Kosalec et al., 2009). 
OCPs, despite having been banned worldwide due to their adverse health 
effects, have frequently been reported in herbal medicines (Chen et al., 2016; 
Kosalec et al., 2009; Perez-Parada et al., 2011; Zhang et al., 2011). OCPs such 
as aldrin and dieldrin are very stable compounds, lending to their persistence 
in the environment for many years after initial use (Zikankuba et al., 2019). 
Pesticide residues, metabolites and degradation products persist in soil, plants 
and animals and have become a primary source of contamination of herbal 
medicines (Zhang et al, 2011). Pesticide residues have been identified in 
medicinal plant products since 1963 (Perez-Parada et al., 2011). 
 
Due to the inevitable presence of environmental pollutants even organically 
grown crops may contain pesticides (Kosalec et al., 2009). Consumers are 
simultaneously exposed to residual pesticides through foods and herbal 
medicines as these medicines do not have a consistent international safety 
guideline regarding pesticide residue contamination (Oh, 2009; Zhang et al, 
2011).  
 
Most pesticides are lipophilic and fat-soluble, allowing for accumulation within 
the food chain and adipose tissues of the human body (Kosalec et al., 2009; 
Zhang et al, 2011; Zikankuba et al., 2019). Babies, children and pregnant 
women are more sensitive to pesticide residues (Zikankuba et al., 2019). The 
primary adverse reactions seen as a result of excessive exposure to pesticide 
residues include neurotoxicity and symptoms of the nervous system, for 
example headaches, dizziness, tremors, restlessness, paresthesia’s and 
convulsions with the possibility of cancer and death (Kosalec et al., 2009; 
Zikankuba et al., 2019). Herbal medicines are often employed by people who 
are in poor health, amplifying their toxicological risk when contaminated (Perez-




2.3.3.4 Trace Elements and Heavy Metals 
The term “heavy metal” refers to a group of elements with high densities and 
highly toxic properties at even low concentrations (AHPA, 2009; Dghaim et al., 
2015; Ezeabara et al.,2014). Several mineral elements essential to human 
nutrition, as well as other elements such as cadmium (Cd) and lead (Pb) which 
are harmful to people even in small concentrations, accumulate in these plants 
(Annan et al., 2013). These elemental impurities in herbal products either arise 
naturally, are added deliberately, or are introduced unintentionally (Eglovitch, 
2014). The negative effects of these impurities on both the environment and 
human health is a cause for public concern (Annan et al., 2013).  
 
Most heavy metal contamination is a result of prior or present use of 
anthropogenic agents such as domestic refuse and industrial or manufacturing 
waste (Ezeabara et al., 2014; Guédon et al., 2008; Okem et al., 2014). These 
heavy metals interfere with the plant physiology and metabolism (Ezeabara et 
al., 2014). Plants provide the primary route of transfer of these heavy metals 
from the soil into people (Dghaim et al., 2015). It has been reported that levels 
of heavy metal contamination can differ between different plant species grown 
in the same environment as well as identical species grown at different sites 
within the same city (Jyoti et al., 2008). Some metals (such as manganese, 
zinc, iron, copper, aluminium and nickel) are essentials nutrients for plants 
which can become phytotoxic at higher concentrations (Filipiak-Szok et al., 
2015). 
 
Heavy metals are persistent in nature due to their long biological half-life and 
non-biodegradability. This also allows for accumulation in the vital organs with 
the consumption of plants and herbs (Ezeabara et al., 2014). Because many 
heavy metals and radioactive nuclides can be found naturally occurring in the 
ground and atmosphere it is important not to further increase overall exposure 
to these noxious elements (Kosalec et al., 2009). Heavy metals are proven to 
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be harmful to people even in small concentrations due to their slow filtration 
rate through the kidneys and nephrotoxic action (Abdulla et al., 2019; Shaban 
et al., 2016), therefore are excreted slowly from the body (Dghaim et al., 2015). 
Metals can build up in human tissues and be stored in excretory organs for 
years or decades (Umar et al., 2016). 
 
There are many health problems co-determined by and associated with a 
persistent intake of small amounts of heavy metals (Ezeabara et al., 2014). 
These include decreased immunological activity, cardiac complaints and 
disturbances of psychological and neurological systems (Dghaim et al., 2015; 
Okem et al., 2014; Shaban et al., 2016). The symptoms of different heavy metal 
poisonings may be significantly similar to one another and without identifying 
the specific toxin, an accurate diagnosis may be difficult (Shaban et al., 2016).   
 
Organisations such as the International Council for Harmonisation (ICH), the 
United States Pharmacopeial Convention (USPC) and the European Medicines 
Agency (EMA), of which South Africa are observing members, have developed 
limits for elemental impurities in herbal products and appropriate 
methodologies to quantify and analyse these impurities (Hineman, 2017). 
However, these limits have not been established on an international level 
(Kosalec et al., 2009) and there is a lack of consistent guidance from national 
health organisations on specific health-based tolerances for heavy metals 
(AHPA, 2009). Both the ICH and USPC aligned a list with levels of 24 elemental 
impurities and classified them into three groups according to their permitted 
daily exposure (PDE) levels (Hineman, 2017) as seen in Table 2.2. PDE is 
defined as the maximum patient exposure to an element, possibly on a chronic 
basis, that is unlikely to produce any adverse health effects (expressed in 
μg/kg/day). To determine the PDE for each element it is important to consider: 
(i) the oxidation state of the element within the product; (ii) all scientific data 
regarding human exposure and safety, (iii) the most recent and applicable 
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animal data and (iv) the route of administration (ICH, 2019). The heavy metals 
most frequently associated with human toxicity are; lead (Pb), mercury (Hg), 
arsenic (As), and cadmium (Cd), but aluminum (Al) and cobalt (Co) have also 
been greatly linked to toxicity (Annan et al., 2013). 
 
Table 2.2: ICH and USPC list of 24 elemental impurities, their classifications 














Cd 1 0,5 0,2 0,3 
Pb 1 0,5 0,5 0,5 
As 1 1,5 1,5 0,2 
Hg 1 3 0,3 0,1 
Co 2A 5 0,5 0,3 
V 2A 10 1 0,1 
Ni 2A 20 2 0,5 
Tl 2B 0,8 0,9 0,8 
Au 2B 10 10 0,1 
Pd 2B 10 1 0,1 
Ir 2B 10 1 0,1 
Os 2B 10 1 0,1 
Rh 2B 10 1 0,1 
Ru 2B 10 1 0,1 
Se 2B 15 8 13 
Ag 2B 15 1 0,7 
Pt 2B 10 1 0,1 
Li 3 55 25 2,5 
Sb 3 120 9 2 
Ba 3 140 70 30 
Mo 3 300 150 1 
Cu 3 300 30 3 
Sn 3 600 60 6 
Cr 3 1100 110 0,3 
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Herbal products have been discovered with evidence of heavy metal 
contamination in several countries of Africa, South America and Asia (Dghaim 
et al., 2015; Zhang et al., 2012). In South Africa, metal poisoning resulting from 
the use of traditional medicines is not uncommon (Okem et al., 2014). The idea 
that some heavy metals have any health benefits is founded on ancient theories 
that are no longer justifiable by modern science and therefore, have no place 
in herbal medicines (Filipiak-Szok et al., 2015). 
 
2.4  Laboratory Methods 
Herbal medicines such as milk thistle as discussed are subject to variation at 
all stages of the manufacturing process (Mudge et al., 2015). In order to confirm 
and standardize the quality of these herbal extracts, laboratory tests should be 
performed and stringent analytical methods applied (WHO, 2011). Examples 
of these methods include; gas chromatography, liquid chromatography and 
inductively coupled plasma-optical emission spectrometry. 
 
2.4.1 Mass Spectrometry 
Mass spectrometry (MS) is an essential tool for qualitative chemical analysis 
(Milman, 2015).  It is superior to any other analytical technique due to its 
unparalleled sensitivity, selectivity, speed and diversity of applications 
(Hoffmann & Stroobant, 2013; Milman, 2015).  
 
The fundamental principle of MS is to generate gas-phase ions from the sample 
compound, fragment the ions, separate them according to their mass-to-charge 
ratio (m/z) and detect them relative to their abundance (Gross, 2011; Hoffmann 
& Stroobant, 2013; Silberring & Smoluch, 2019).  
 
A mass spectrometer consists of several basic elements represented 
schematically in Figure 2.3. There are many different technologies available to 
perform both ionization and mass analysis which can be used in different 
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combinations, therefore this results in several types of mass spectrometers 
(Pitt, 2009).  
 
Figure 2.3: The general scheme of a mass spectrometer (Gross, 2011). 
 
The steps involved in an MS experiment generally consist of: (i) introducing the 
sample; (ii) ionization of the analyte; (iii) analysis of mass; (iv) detection of ions 
and (v) data processing and result interpretation (Falck & Niessen, 2015). 
There are over 50 techniques available to perform ionization of the analyte 
(Falck & Niessen, 2015) and the appropriate selection is based on the analyte 
mass as well as relative hardness or softness (Gross, 2011). A high or 
atmospheric pressure vacuum is required inside a mass spectrometer for 
analyte ionization, mass analysis and ion detection (Falck & Niessen, 2015; 
Silberring & Smoluch, 2019). After analyte ionization the ions are transported 
to the mass analyzers where ions are separated and their characteristic m/z 
ratios are determined (Silberring & Smoluch, 2019). Several types of mass 
analyzers exist, and they all use static or dynamic electric and magnetic fields 
either alone or in combination (Hoffmann & Stroobant, 2013). Once ions are 
separated, they are introduced into the detector where the quantum ion current 
is converted into an electrical current, the intensity of which is relayed and 
transcribed by information software (Silberring & Smoluch, 2019). This process 
produces a mass spectrum of the molecule in the form of a plotted function of 




2.4.2 Mass Spectrometry- Chromatography Coupling 
The International Union of Pure and Applied Chemistry (IUPAC) defines 
chromatography as the physical method of separation in which the components 
to be separated are distributed between two phases, the stationary phase and 
the mobile phase which moves in a definite direction (McNair et al., 2019). 
Various chromatographic techniques are used for separation of complex 
mixtures for analysis by a mass spectrometer (Hoffmann & Stroobant, 2013). 
The incorporation of a separation technique creates further dimension for the 
analytical measurement and a hyphen is used to indicate the pairing of a 
separation technique with MS, thus the group term is hyphenated methods 
(Gross, 2011). All chromatographic systems follow a scheme similar to that 
seen in Figure 2.4. A pump produces a controlled flow of mobile phase or eluent 
which is used to transport the injected sample to the analytical column. The 
sample is separated in the column and the analytes are detected by the chosen 
detector system (Smoluch et al., 2019). 
 
Figure 2.4: A simplified schematic diagram of a chromatographic system 
(Smoluch et al., 2019) 
 
2.4.3 Gas Chromatography- Mass Spectrometry 
GC is a universal gas phase method of separation of volatile analytes in 
complex mixtures (Gross, 2011). It has been used to separate both organic and 
inorganic gases, liquids and solids once dissolved in a volatile solvent (McNair 
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et al., 2019). This analytical technique makes use of the different boiling points 
of the constituents within the sample in order to achieve separation (Cumeras 
& Correig, 2018). GC has been successfully coupled with MS since the 1950’s 
(Pitt, 2009). In a typical GC-MS experiment the sample is injected into the input 
port and then it is vaporized and transported by a carrier gas and mobile phase 
such as helium (He), hydrogen (H2), nitrogen (N2), or argon (Ar) into a silica 
analytical GC column (Drabik, 2019). The GC column is coated with the 
stationary phase and is increasingly heated while the carrier gas moves the 
sample through the column to the detector or mass spectrometer (Cumeras & 
Correig, 2018; Drabik, 2019). Two subclassifications of GC exist based on the 
state of the stationary phase; gas-solid chromatography (GSC) and gas-liquid 
chromatography (GLC) (McNair et al., 2019). As the sample moves through the 
column, it fragments and reacts with the stationary phase under the influence 
of the increasing temperature based on their relative vapor pressures and 
affinities for the stationary phase (Drabik, 2019; McNair et al., 2019). The more 
volatile the components of the compound, the sooner they are eluted from the 
column (Drabik, 2019). The point at which the solutes are eluted is recorded as 
their retention times (Gross, 2011).  
 
2.4.4 Liquid Chromatography- Mass Spectrometry 
LC is used for non-volatile, thermally unstable, ionic or highly polar compounds 
not suitable for GC (Hoffmann & Stroobant, 2013; Niessen, 2019), therefore 
LC-MS is generally more pertinent than GC-MS due to its larger range of 
molecules that can be analyzed (Pitt, 2009). Most commonly high- performance 
liquid chromatography (HPLC) and ultra-high-performance liquid 
chromatography (UHPLC or UPLC) are utilized for LC-MS work (Gross, 2011).  
 
In LC the mobile phase is a mixture of solvents of various polarities and the 
stationary phase is a highly porous adsorbent material packed into a stainless-
steel chromatographic column (WHO, 2019). After a sample is prepared it is 
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injected via a valve-controlled injection port into the LC column with the aid of 
a pump system (Drabik, 2019). The pump system delivers the mobile phase 
from a solvent reservoir at a constant flow rate and high pressure (WHO, 2019). 
Once in the LC column, the compounds separate based on their adsorption or 
desorption to or from the stationary phase (Drabik 2019).  
 
LC is the most used separation technique to be coupled with various types of 
mass spectrometers (Drabik, 2019) however, due to the incompatibility of MS 
ion sources with a continuous liquid stream this coupling did not take place until 
the 1980’s when an electrospray ion source was developed (Pitt, 2009). LC-
MS has since promoted the development of various new ionization techniques, 
the selection of which is based on the compound polarity and molecular mass 
(Gross, 2011). Most existing LC-MS instruments are based on atmospheric 
pressure ionization (API) techniques (Cappiello & Palma, 2018) for example, 
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI) 
and atmospheric pressure photoionization (APPI) (Gross, 2011; Hoffmann & 
Stroobant, 2013).  
 
At the API interface the LC column effluent is introduced and subsequently 
nebulized by an electric field and ionized into a fine spray of charged droplets 
at atmospheric pressure. Gas phase ions are produced from the charged 
droplets and they flow through the ion-sampling orifice to a mass analyzer and 
detector (Niessen, 2019).  
 
2.4.5 Inductively Coupled Plasma- Mass Spectrometry 
Inductively coupled plasma-mass spectrometry (ICP-MS) is a universal 
analytical technique which can be used to characterize the elemental 
composition of almost any sample (Baxter & Wilschefski, 2019; Pawlaczyk & 
Szynkowska, 2019). ICP-MS is a widely used technique due to its multi-
element analysis capabilities, allowing for numerous elements to be measured 
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during a single analysis (Baxter & Wilschefski, 2019), as well as its short 
analysis time, high sensitivity and reliability (Ammann, 2007; Pawlaczyk & 
Szynkowska, 2019). Detection of multi-element isotopes is also possible with 
LC-MS due to its low detection limits and high spectral resolution (Ammann, 
2007).  
 
An ICP mass spectrometer consists of: (i) a sample introduction system; (ii) 
inductively coupled plasma ion source; (iii) ion interface; (iv) ion optics; (v) mass 
analyzer and (vi) detector (Baxter & Wilschefski, 2019; Pawlaczyk & 
Szynkowska, 2019). Samples are introduced via the sample introduction 
system where they are subsequently nebulized and transferred in the carrier 
gas to the inductively coupled argon plasma (Baxter & Wilschefski, 2019). The 
ICP is a high temperature ion source providing temperatures of approximately 
5500°C (Ammann, 2007) and is usually a result of heating by a plasma torch 
(Gross, 2011; Pawlaczyk & Szynkowska, 2019). The ICP serves to atomize 
and ionize the nebulized droplets at atmospheric pressure (Ammann, 2007; 
Baxter & Wilschefski, 2019; Pawlaczyk & Szynkowska, 2019). The ions 
generated are then passed through the ion interface where electrostatic lenses 
form, focus and guide the ion beam into the quadrupole mass analyzer in a 
vacuum where they are separated according to their m/z ratios and measured 
by the detector (Baxter & Wilschefski, 2019; Pawlaczyk & Szynkowska, 2019). 
The resulting data directly correlates with the total elemental composition of the 
sample (Ammann, 2007). 
 
2.5  Related Research 
A study conducted by Okem et al. (2014) tested the levels of heavy metals 
present in herbal medicines purchased from South African commercial stores 
as well as open street markets. Using ICP coupled with optical emission 
spectrometry (OES), high levels of mercury, arsenic, aluminium and iron were 




In a study done on the quality assessment of South African herbal medicines, 
a technique using HPLC and a diode array detector (DAD) was developed and 
chemical marker fingerprints of 60 individual plant species were created. This 
coupled with taxonomy can be used to establish a code of practice for the 




























3.1  Facilities Utilised 
The LC-MS analysis for the active constituents and the GC-MS analysis for 
pesticide residues was completed by the Central Analytical Facilities of the 
University of Stellenbosch. The analysis for heavy metals and trace elements 
by ICP-MS was completed at the University of Johannesburg (Appendix A). 
 
3.2  Procurement 
Six different brands of commercial Silybum marianum L. Gaertn. (milk thistle) 
products were procured from various pharmacies and health stores around 
South Africa. 
 
3.3  Research Sample 
Samples were removed from the packing and separated into their individual 
batches and then randomly labeled (in order to ensure anonymity and eliminate 
bias). The capsules purchased were opened and the powder inside the capsule 
as well as the capsules themselves were weighed to determine the mass as 
declared on the package label. 
 
3.3.1 Inclusion Criteria 
Products were included in this study if the dosage form was a capsule, if they 
claimed to contain Silybum marianum L. Gaertn. as the only active ingredient 
and if they were available at pharmacies and health shops in South Africa. 
 
3.3.2 Exclusion Criteria 
Products were excluded from this study if they have ingredients additional to 
Silybum marianum L. Gaertn and are in a dosage form other than a capsule.  
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3.4 Study Design 
This is a quantitative non-interventional experimental exploratory study which 
seeks to investigate the quality of various milk thistle products available in 
South Africa using LC-MS, GC-MS and ICP-MS.  
 
3.5 Determination of Flavonolignans Using LC-MS 
3.5.1 Sample Preparation 
One capsule from each of the six Silybum marianum L. Gaertn samples was 
supplied to the University of Stellenbosch.  The contents of the capsules were 
extracted by a laboratory technician with 10 mL methanol for 1 hour in 
ultrasonic bath. The samples were subsequently diluted 5, 25 and 50 fold 
depending on the concentration of the silymarins. 
 
3.5.2 LC-MS Analysis 
LC-MS was performed using a Waters UPLC system. Chromatographic 
separation was performed on an ACQUITY UPLC T3 HHS (2,1 mm x 150 mm 
x 1,7 um) (serial 0211382491518) (Waters Corporation, Milford, MA, USA) 
equipped with a diode array. Solvent A (mobile phase A) was water. Mobile 
phase B was methanol:acetonitrile:isopropanol, 49:49:2, with 1% formic acid. 
The column temperature was ambient at 40°C. The UPLC flow rate was 0,35 
mL/min. A sample solution of 5 μL was injected into the UPLC system. A mobile 
phase gradient elution program was used with the percentage of B in A varying 
as follows: initial concentration, 10% B; 1 min, 15% B; 15 min, 52% B; 16 min, 
100% B;17.10min, 10% B. The pressure limits were set as follows: low, 30 psi; 
high, 15000 psi during the elution process. The Synapt G2 electrospray 
ionization source (Waters Corporation, Milford, MA, USA) was operated in 
positive ionization mode (ESI+) and the cone voltage was set at 30 V and used 
to detect the flavonolignans. The milk thistle dry extract from European 
Pharmacopeia (Y0001687) was utilised as the certified reference material 
(Appendix B). Each sample was analysed three times. 
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3.5.3 Method Validation and Calibration 
The LC-MS method was validated according to the ICH guidelines “Validation 
of Analytical Procedures: Text and Methodology Q2(R1)” (ICH, 2014). The 
method was validated evaluating the following parameters: linearity, limit of 
detection (LOD), limit of quantification (LOQ), precision and accuracy. The 
calibration curve constructed during validation and optimisation for the 
reference standard milk thistle dry extract from European Pharmacopeia 
(Y0001687) was linear. The correlation coefficient (R²) was 0.9998, confirming 
the linearity of the analytical range for the individual flavonolignans. The 
concentrations used for the calibration curve as well as the calibration curve 
can be seen in Appendix C. A good resolution of all flavonolignans studied was 
achieved with the chosen chromatographic conditions. 
 
3.6 Determination of Pesticides using GC-MS 
3.6.1 Sample Preparation 
The samples were weighed into individual solid-phase microextraction (SPME) 
vials and 10ml of a 20% sodium chloride (NaCl) solution was added. Both the 
samples and calibration standard were treated in a similar way. The mixtures 
were vortexed for 60 seconds. The SPME vials with the samples were then 
equilibrated for 10 minutes at 70°C in the CTC autosampler incubator, shaken 
at 250 rpm. The headspace of the sample was analysed with a red 
polydimethylsiloxane (PDMS) SPME fibre (100 um). The PDMS coated fibre 
was exposed to the sample headspace for 30 min at 70°C. After extraction, 
desorption of the volatile compounds from the fibre coating was carried out in 
the injection port of the GC–MS for 10 minutes. 
 
3.6.2 GC-MS Analysis 
1µl of the sample was injected on a Thermo TSQ 8000 triple quadrupole MS 
(Thermo Fisher, Waltham, MA, USA) operated in a selected reaction 
monitoring (SRM) mode. Separation of the pesticides was performed on a 
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Thermo 1310 gas chromatograph coupled with a non-polar ZB-5Ms (30 m x 
0.25 mm ID x 0.25 µm film thickness) capillary column. The ionization source 
temperature was set at 250 °C and emission current of 50 µA was used with 
Argon collision. The oven program was as follows: 80 °C for 2 min; and then 
ramped up to 200 °C at 10 °C min−1 and held for 5 min and finally ramped up 
to 320 °C at 25 °C min-1 and held for 10 min. Helium at a constant flow of 1 
ml/min was used as carrier gas. The transfer line temperature was maintained 
at 280 °C. The injector was maintained at 250 °C. Each sample was analysed 
three times (Beceiro-González et al., 2007). 
 
3.6.3 Method Validation and Calibration 
The method was validated evaluating the following parameters: linearity, LOD, 
LOQ, precision and accuracy. The calibration curves constructed during 
validation and optimisation for the reference standard material were linear. The 
certificate of analysis, conditions for the certified reference material, the 
concentrations used for the calibration curves as well as some of the calibration 
curves can be seen in Appendix D. A good resolution of all pesticides studied 
was achieved with the chosen chromatographic conditions. 
 
3.7 Determination of Heavy Metals Using ICP-MS 
3.7.1 Microwave Digestion  
For sample preparation a microwave acid-assisted system was used to digest 
the contents of the milk thistle capsules. The samples (0,5 g dry weight), as 
well as a blank sample, were placed in Teflon vessels and 10 ml of 55% nitric 
acid (HNO3) was added. The blank consisted of 10 ml 55% HNO3. The vessels 
were then placed into the carousel of the Mars 6 microwave digestion system 
and the plant material temperature program was selected. This temperature 
program was as follows:  
• Stage 1: 2 min heating from ambient to 170 °C;  
• Stage 2: 3.30 min heating to 180 °C and  
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• Stage 3: 9.30 min held at 180 °C.  
After the digestion was complete, each sample was filtered, and the resultant 
solutions were transferred into 50 ml volumetric flasks. The remaining volume 
was made up with demineralised water and shook thoroughly. These samples 
were stored in high-density polyethylene bottles until analysis.  
 
3.7.2 Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)  
An ICP-MS, NexION 300s (Perkin Elmer, Waltham, MA, USA) instrument was 
utilised for the elemental analysis. The operating conditions for the ICP-MS 
instrument were as follows: radiofrequency power of 1 kW; viewing geometry 
axial; argon gas used as plasma gas flow at the rate of 15,0 L min−1 ; auxiliary 
gas flow rate 1,50 L min−1 ; nebuliser gas flow rate 0,75 L min−1 ; and replicate 
reading time 9,0 s. Each sample was analysed three times (Okem et al., 2014).  
 
3.7.3 Method Calibration and Validation 
The method was validated evaluating the following parameters: linearity, LOD, 
LOQ, precision and accuracy. Stock and working standard solutions were be 
prepared by using ICP-MS standard solutions of elements tested for which 
include aluminum (Al), cadmium (Cd), copper (Cu), iron (Fe), lead (Pb), nickel 
(Ni), manganese (Mn) and zinc (Zn) (Appendix E). The standard stock solutions 
(1000 ppm) were diluted to obtain working standard solutions ranging from 1 
ppm to 10 ppm and stored at 4°C. A calibration curve was plotted between 
measured absorbance and concentration (ppm) and revealed linearity 
(Appendix F).  
 
3.8 Data and Statistical Analysis 
The data sets were subjected to statistical analyses using SPSS statistical 
package version 21.0 for Windows. The researcher collated, reviewed and 




3.9 Reliability and Validity Measures  
The extraction and entry of the data was double-checked by an independent 
person. The reliability and validity of the study was enhanced by ensuring that 
the procedure is feasible and valid prior to commencement of the study. 
 
3.10 Ethical Considerations 
All methods and techniques utilised followed Good Laboratory Practices (GLP) 
according to the South African GLP and GMP standards. The researcher 
underwent laboratory training, followed appropriate safety guidelines and wore 
protective gear. This study was supervised by a qualified laboratory technician. 
This study used blinding to prevent bias and all products remained unknown to 
the researcher until all the data was recorded and processed. Product names 
will not be disclosed in the dissertation and all negative findings have been 
reported to SAHPRA in the form of a report per product that has been submitted 
via their website (sahpracm.org.za). 
 
The Higher Degrees Committee (HDC) as well as Research Ethics Committee 
(REC) of the Faculty of Health Sciences at the University of Johannesburg 
confirmed that the research proposal for this study complies with the ethical 















Six Silybum marianum L. Gaertn. (milk thistle) supplements were purchased 
from different pharmacies and health stores in Johannesburg, South Africa. 
Three different tests were conducted on the samples to evaluate the different 
components of the samples. The first set of samples were analysed on liquid 
chromatography–mass spectrometry (LC-MS) to evaluate them for the 
presence of flavonolignans, especially silymarin, the main active component in 
milk thistle. The other two tests were conducted were gas chromatography–
mass spectrometry (GC-MS) and inductively coupled plasma–mass 
spectrometry (ICP-MS) in order to assess the samples for pesticide residues, 
and heavy metals as well as trace elements respectively.   
 
4.2 LC-MS Analysis for Flavonolignan Content  
The constituents of the silymarin standardised extracts were identified by 
comparing the retention time values with those of the reference peaks from 
silymarin obtained from European Pharmacopeia (Y0001687). Figure 4.1 
displays the chromatogram with the reference peaks generated from the 
European Pharmacopeia (Ph. Eur) reference standard (RS).  
 
The measurements for each sample were carried out in triplicate and the 
average total of each active constituent present in the samples as identified 
through LC-MS analysis is shown in Table 4.1 and the raw data in Appendix I. 
The graph of these findings is in Appendix J. These results are presented per 
gram and not per capsule as capsule size varied with brand as well as 
flavonolignan content. The average silymarin present in each capsule for each 











Table 4.1: Average constituent concentrations and total silymarin content (mg/g) of milk thistle samples (mean ± 
SD). 
 




Silibinin A Silibinin B Taxifolin Silichristin Silidianin 
Total 
Silymarin 
Sample 1 2,34 ±0,19 0,87 ±0,03 3,51 ±0,19 6,28 ±0,09 1,38 ±0,13 5,37 ±0,19 1,69 ±0,30 20,26 ±0,50 
Sample 2 10,15 ±0,17 2,56 ±0,50 21,68 ±0,13 31,87 ±0,21 3,16 ±0,06 19,92 ±0,07 5,94 ±0,06 92,97 ±0,52 
Sample 3 15,38 ±0,50 5,89 ±0,28 29,94 ±1,15 50,18 ±0,53 10,35 ±2,04 35,00 ±0,25 9,30 ±0,49 145,70 ±2,36 
Sample 4 11,87 ±0,39 4,56 ±0,35 20,34 ±0,33 35,05 ±0,36 7,45 ±0,69 27,85 ±0,47 8,95 ±0,94 108,63 ±2,81 
Sample 5 8,49 ±0,32 3,30 ±0,22 7,29 ±0,03 16,74 ±0,18 5,33 ±0,15 20,71 ±0,44 4,56 ±1,14 61,08 ±2,07 







As seen in Table 4.2, sample 3 contained the highest amount of total 
flavonolignan with an average silymarin content of 145,7 mg/g and 62,7 mg of 
silymarin per capsule, followed by sample 4 with an average silymarin content 
of 108,9 mg/g or 45,6 mg/capsule. The two samples with the lowest average 
flavonolignan content were sample 6 with 9,83 mg/g or 5,1 mg/capsule and 
sample 1 with 20.2 mg/g or 5,1 mg/capsule. The differences in the total 
silymarin can also be seen in Table 4.1 where samples 6 and 1 have the lowest 
levels of all the different flavonolignans, while samples 3 and 4 have the highest 
levels across all flavonolignans tested.    
 
Table 4.2: Mass of whole capsule (mg) and contents of capsule (mg), and 












Sample 1a 0,3467 0,2539 20,50 5,2 
Sample 1b 0,3467 0,2539 20,49 5,2 
Sample 1c 0,3467 0,2539 19,68 5,0 
Sample 1 
ave 0,3467 0,3467  20,22 5,13 
Sample 2a 0,5362 0,4368 93,18 40,7 
Sample 2b 0,5362 0,4368 92,37 40,3 
Sample 2c 0,5362 0,4368 93,36 40,8 
Sample 2 
ave 0,5362 0,4368 92,97 40,6 
Sample 3a 0,5262 0,4309 148,36 63,9 
Sample 3b 0,5262 0,4309 144,87 62,4 
Sample 3c 0,5262 0,4309 143,86 62,0 
Sample 3 
ave 0,5262 0,4309 145,70 62,7 
Sample 4a 0,5183 0,4195 111,76 46,9 
Sample 4b 0,5183 0,4195 106,34 44,6 




ave 0,5183 0,4195 108,63 45,6 
Sample 5a 0,7014 0,5783 63,84 36,3 
Sample 5b 0,7014 0,5783 61,61 35,6 
Sample 5c 0,7014 0,5783 58,81 34,0 
Sample 5 
ave 0,7014 0,5783 61,42 35,4 
Sample 6a 0,6126 0,515 9,85 5,1 
Sample 6b 0,6126 0,515 9,82 5,1 
Sample 6c 0,6126 0,515 9,81 5,1 
Sample 6 
ave 0,6126 0,515 9,83 5,1 
mg – milligram, mg/g – milligram per gram, mg/cap – milligram per capsules, ave – 
average  
 
According to the literature review, silybin is the most therapeutically active 
constituent of milk thistle and the constituent that is most often measured as a 
marker of quality (Hudson, 2012; Vania, 2012). The content of silybin (A and 
B) is the only parameter that is given for silymarin in the pharmacopoeias, e.g.: 
≥50,0% and ≤ 60,0% of silymarin calculated as silybin by HPLC according to 
Ph. Eur. As seen in Table 4.3, the percentage of silybin present in each capsule 
varies from 39% in sample 5 to 57% in sample 2. 
 




















20,22 92,97 145,70 108,63 61,42 9,83 
% Silibinin of 
total 
Silymarin 
48,42 57,60 54,99 50,99 39,12 50,76 




4.2.1 Sample 1 
When comparing the chromatographic peaks for sample 1 (Figure 4.2) with that 
of the Ph. Eur RS (Figure 4.1), all the necessary peaks representing the active 
constituents of silymarin are present. The silibinin content of sample 1, although 
having silibinin A and B peaks that are similar to the reference, falls short of the 
recommended ≥50,0% and ≤ 60,0% range of silibinin at 48,42%. The total 
average flavonolignan content of this sample was the second-lowest with 20,22 
mg/g and 5,13 mg per capsule.  
 
 
Figure 4.2: The resultant chromatogram from the LC-MS analysis of sample 1 
 
4.2.2 Sample 2 
The peaks seen in the representative chromatogram of sample 2 (Figure 4.3) 
are similar to that of the reference standard in terms of intensity and position. 
The total average flavonolignan content of this sample was the third highest 
with 92,97 mg/g and 40,6 mg per capsule. Although this sample did not have 
the highest total silymarin content of the six samples, the percentage of 
silibinins was within the recommended parameters at 57,60% and was the 
highest amongst the six samples.  
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Figure 4.3: The resultant chromatogram from the LC-MS analysis of sample 2 
 
4.2.3 Sample 3  
The chromatogram resulting from the LC-MS analysis of sample 3 
demonstrates the correct peaks associated with silymarin. As seen in Table 
4.2, the greatest average flavonolignan content amongst all six tested samples 
was sample 3 with 145,70 mg/g and 62,7 mg per capsule. The percentage of 
silibinins present in this sample measured 54,99% and therefore it is one of 
four samples that fall within the prescribed silibinin parameters.  
 
 
Figure 4.4: The resultant chromatogram from the LC-MS analysis of sample 
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4.2.4 Sample 4 
Sample 4 has a resultant chromatogram that closely resembles the 
chromatogram of the reference standard. The average total flavonolignan 
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content of sample 4 was 108,63 mg/g and 45,6 mg per capsule, making it the 
second highest of the analysed samples, but with a calculated percentage of 
50,99% silibinin, sample 4 only just falls within the range of recommended 
silibinin values for a standardised silymarin extract.  
 
Figure 4.5: The resultant chromatogram from the LC-MS analysis of sample 4 
 
4.2.5 Sample 5 
The chromatographic fingerprint produced from the LC-MS analysis of sample 
5 (Figure 4.7) demonstrated many differences from the Eur. Ph. RS (Figure 
4.1).   The total percentage of silibinins in sample 5 is the lowest amongst the 
analysed samples and at 39,12% also does not fulfill the requirements of 50-
60%. Though the sample has the lowest percentage silibinin, it does not have 
the lowest total average flavonolignan content. The total average flavonolignan 
content is 61.42 mg/g and 35,3 mg per capsule.  
 
 
Figure 4.6: The resultant chromatogram from the LC-MS analysis of sample 5 
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4.2.6 Sample 6  
As seen in Figure 4.7, the chromatographic representation of sample 6 shows 
identical peaks to those seen in the reference sample. The 50,76% total 
silibinins detected in this sample means that it falls within the recommended 
guideline values. Sample 6 has the lowest amount of average total 




Figure 4.7: The resultant chromatogram from the LC-MS analysis of sample 6 
 
4.3 GC-MS Analysis for Pesticide Residues 
The six commercial milk thistle supplements that were selected for the study 
were analysed for the residues of 15 organochlorine pesticides namely Aldrin, 
α-BHC, β-BHC, γ-BHC (Lindane), cis-Chlordane, trans-Chlordane, 4,4'-DDD, 
4,4'-DDE, Dieldrin, Chloroanthil, Chlorobenzilate, Endrin, Heptachlor, 
Hexachlorobenzene and Hexachloropentadiene. The pesticide residues were 
identified by comparison of retention time values with those of the reference 
peaks obtained from the certified reference standard. Figure 4.8 displays the 
chromatogram with the reference peaks generated from the reference 
standard. The conditions of the standard reference material, including retention 
time values, can be seen in Appendix D. 
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Figure 4.8: A chromatogram of the standard used in the GC-MS analysis. 
 
The results of the GC-MS analysis for the residues of 15 pesticides in the six 
milk thistle samples are shown in Table 4.4. No pesticides were detected in any 



















Table 4.4: Results of the GC-MS analysis for the residues of 15 pesticides in 














Aldrin  ND ND  ND  ND  ND  ND  
α-BHC ND ND ND ND ND ND 
β-BHC ND ND ND ND ND ND 
γ-BHC (Lindane)  ND ND ND ND ND ND 
cis-Chlordane  ND ND ND ND ND ND 
trans-Chlordane  ND ND ND ND ND ND 
4,4'-DDD ND ND ND ND ND ND 
4,4'-DDE  ND ND ND ND ND ND 
4,4'-DDT ND ND ND ND ND ND 
Dieldrin ND ND ND ND ND ND 
Chloroanthil ND ND ND ND ND ND 
Chlorobenzilate ND ND ND ND ND ND 
Endrin ND ND ND ND ND ND 
Heptachlor  ND ND ND ND ND ND 
Hexachlorobenzen
e ND ND ND ND ND ND 
Hexachloropentadi
ene ND ND ND ND ND ND 
ND: Not detected 
 
4.4  ICP-MS Analysis for Heavy Metals and Trace Elements 
The eight heavy metal and trace element concentrations (μg/g) of the six of 
commercial milk thistle supplement samples are shown in Table 4.5. The graph 
of these findings is in Appendix K. The measurements for each sample were 
carried out in triplicate. Heavy metals and trace elements that were tested were 
iron (Fe), nickel (Ni), copper (Cu), zinc (Zn), manganese (Mn), aluminium (Al), 
cadmium (Cd) and lead (Pb).  
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Table 4.5: Average heavy metal and trace element concentrations (mean ± SD µg/g). 
 
Fe Ni Cu Zn Mn Al Cd Pb Total 
SAMPLE 1 190,63 
±2,19 
0,61 ±0,01 1,39 ±0,02 45,07 
±0,27 
6,03 ±0,15 157,74 
±3,35 
0,00 ±0,01 0,26 ±0,00 401,726 
SAMPLE 2 11,39 
±1,16 
0,23 ±0,01 0,30 ±0,00 0,13 ±0,09 0,57 ±0,05 2,44 ±0,43 0,00 ±0,01 0,03 ±0,00 15,0981 
SAMPLE 3 6,32 ±0,25 0,17 ±0,02 0,16 ±0,00 0,00 ±0,05 0,34 ±0,02 3,93 ±0,42 0,03 ±0,01 1,17 ±0,01 12,1143 
SAMPLE 4 208,33 
±1,91 








0,05 ±0,01 0,85 ±0,01 406,860 










0,25 ±0,01 1,24 ±0,01 3349,81 
SAMPLE 6 334,57 
±5,30 








0,27 ±0,03 1,41 ±0,02 708,818 
Al – aluminium; Cd – cadmium; Cu – copper; Fe – iron; Pb – lead; Mn – manganese; Ni – nickel; Zn – zinc.   
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4.4.1 Sample 1 
Variable concentrations of heavy metals and trace elements can be seen in 
sample 1, ranging from 190,63 ±2,19 (Fe) to 0,00 ±0,01 (Cd). The 
concentrations of the analysed elements in sample 1 were as follows: Fe > Al 
> Zn > Mn > Cu > Ni > Pb > Cd. Fe was the element of the highest average 
concentration (190,63 ±2,19 ug/g). The toxic element Cd was not detected in 
the sample. The total concentration of analysed elements was 401,73 ug/g, 
making sample 1 the third least contaminated sample out of the six samples.  
 
All trace elements and heavy metals detected in this sample were within the 
WHO permissible limits (PL).  
 
4.4.2 Sample 2 
Sample 2 had the second lowest total average contamination amongst the six 
samples with a value of 15,09813 ug/g. The concentrations of the analysed 
elements in sample 2 were as follows: Fe > Al > Mn > Cu > Ni > Zn > Pb> Cd. 
All the analysed impurities of this sample were within guideline parameters. 
When compared to the other five samples, sample 2 had the lowest 
concentrations of the two class I elemental contaminants Cd (0,00 ±0,01 ug/g, 
which is the same Cd concentration as sample 1) and Pb (0,03 ±0,00 ug/g), as 
well the lowest Al concentration (2,44 ±0,43 ug/g).  
 
All trace elements and heavy metals detected in this sample were within the 
WHO PL. 
 
4.4.3 Sample 3 
The total concentration of the eight elemental impurities analysed in sample 3 
was 12,1143 ug/g, making it the least contaminated sample. The 
concentrations of the analysed elements in sample 3 were as follows: Fe > Al 
> Pb > Mn > Ni > Cu > Cd > Zn. Although Fe (6,32 ±0,25 ug/g) had the highest 
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reading for this sample, it was the lowest concentration of Fe detected amongst 
all samples. Sample 3 also had the lowest levels of Ni (0,17 ±0,02 ug/g), Cu 
(0.17 ±0,02 ug/g), Zn (0,00 ±0,05 ug/g) and Mn (0,34 ±0,02 ug/g) in comparison 
to the rest of the samples.  
 
According to the permitted concentration of elemental impurities in drug 
products dosed at a maximum daily dose of 10 g/day laid out by the 
International Council for Harmonisation (ICH) and the US Pharmacopoeia 
(USP), the concentration levels of Pb (1,17 ±0,01 ug/g) in sample 3 are above 
the permissible limit of 0,5 ug/g. Sample 3 had the third highest concentration 
of Pb out of the six samples that were tested.  
 
4.4.4 Sample 4 
The concentrations of the analysed trace elements and heavy metals detected 
in sample 4 were as follows: Fe > Al > Zn > Mn > Cu > Ni > Pb > Cd. The total 
of the concentrations of these 8 elements was 406,86 ug/g, making it the third 
highest of the tested samples. Sample 4 has variable concentrations of the 
analyte elements, ranging from 208,33 ±1,91 (Fe) to 0,05 ±0,01 (Cd).  
 
Ni, a class 2A toxic element, was detected in concentrations above the WHO 
permissible limit of 2,0 ug/g at 4,55 ±0,06 ug/g, as was the class I toxic element 
Pb (0,85 ±0,01 ug/g.)  
 
4.4.5 Sample 5 
Sample 5 had the greatest total concentration of elemental impurities with 
3349,81 ug/g. This was due to the very high concentrations of Al (2162,84 
±18,75 ug/g) and Fe (1086,88 ±10,48 ug/g). The greatest concentrations of Mn 
(51,67 ±0,61 ug/g) and Ni (17,77 ±0,18 ug/g) were also seen in this sample. 
The concentrations of the analysed elements in sample 5 varied considerably 




The class 2A toxic element Ni was detected in the highest concentration in this 
sample at 17,77 ±0,18 ug/g, and is above the WHO permissible limits of 2,0 
ug/g. The toxic class I elements Cd (0,25 ±0,01 ug/g) and Pb (1,24 ±0,01 ug/g) 
were also detected in this sample, with Pb measuring above the guideline of 
permissible limits set by the ICH and USP.  
 
4.4.6 Sample 6 
The sample with the second highest total average concentration of 708.82 ug/g 
was sample 6. The concentrations of the analysed heavy metals and trace 
elements in this sample were as follows: Fe > Al > Zn > Mn > Cu > Ni > Pb > 
Cd. The levels of Cu (22,86 ±0,36 ug/g), Zn (60,29 ±0,58 ug/g), and the toxic 
class I elements Cd (0,27 ±0,03 ug/g) and Pb (1,41 ±0,02 ug/g) were the 
highest in this sample compared to the other six samples.  
 
The presence of Pb with an average concentration of 1,41 ±0,02 ug/g and Ni 
with a concentration of 5,72 ±0,06 ug/g makes sample 6 above the 0,5 ug/g 



















This study assessed the presence and levels of the active constituents and 
contaminants (pesticide residues, heavy metal and trace elements) of the six 
Silybum marianum L. Gaertn. (milk thistle) products that were purchased from 
pharmacies and health shops in Johannesburg, South Africa. The results were 
obtained using liquid chromatography–mass spectrometry (LC-MS) for the 
presence of flavonolignans (especially silymarin), gas chromatography–mass 
spectrometry (GC-MS) for pesticide residues, and inductively coupled plasma–
mass spectrometry (ICP-MS) for heavy metals and trace elements.   
 
Following the presentation of the results in Chapter 4, this chapter will now 
present an explanation of the obtained results with reference to the study and 
other potential influencing factors contained herein. The conclusion of this 
chapter will attempt to present an outcome of the quality evaluations performed 
in this study. 
 
5.2  LC-MS Analysis for Flavonolignans  
For a product to have consistent and reproducible quality, the constituent 
content must be reported in an expected range (EMA, 2006). Standardised 
Silybum marianum extracts contain 70–80% (w/w) of silymarin and this 
standard has been widely adopted for the production of products that contain 
this herb (Abenavoli et al., 2018; Eklund et al., 2009; Lee et al., 2007).  
 
The products that were used for the preparation of sample 1-6 had the following 
information on their respective labels. The level of silymarin for each sample, 




Table 5.1: Label information of products used.   
Product:  Composition per capsule:  Quantity: 
Product 1 Milk thistle extract (Silybum marianum) leaves 
powder 
300 mg 
Milk thistle extract (Silybum marianum) extract (80% 
silymarin) 
30 mg  
Silymarin declared 24 mg 
Product 2 Milk thistle extract 200 mg 
Silymarin declared  NP 
Product 3 Milk thistle extract 250 mg 
Providing silymarin  200 mg 
Silymarin declared 200 mg 
Product 4 Milk thistle seed powder 200 mg 
Milk thistle extract (80%) silymarin 200 mg 
Silymarin declared 160 mg 
Product 5 Raw milk thistle herb powder 300 mg 
Standardised milk thistle seed powdered extract 175 mg 
Total flavonoids including silymarin (80%) 140 mg 
Silymarin declared 112 mg 
Product 6 Milk thistle seed powder 400 mg 
Silymarin declared  NP 
NP – not provided 
 
As seen in Table 5.1, the labels of products 1, 3, 4 and 5 give information 
regarding the quantity of extract or powder used per capsule, as well as an 
indication of the levels of silymarin per capsule. Product 2 and product 6 only 
state “milk thistle extract” and “milk thistle powder” on their labels, without any 




In a study conducted by Gabriels et al. (2012) the researchers analysed the 
labels of 40 products that were either locally manufactured in South Africa or 
imported and sold here.  95% of products contained a warning statement on 
the label. 85% of the nutritional supplement products had a disclaimer on the 
label. 98% of the nutritional supplement product labels included some claim on 
the label. In conclusion, this study highlighted that this information, in particular, 
needs to be regulated and enforced as part of the labelling process, to ensure 
that the consumer can make an informed choice. 
 
In a study conducted by Gabriels and Lambert (2013) in Cape Town, 
Johannesburg and Pretoria in South Africa, they use a self-administered 
questionnaire to determine if label information influenced purchasing decisions. 
Out of 239 participants that completed the questionnaire, 132 (68%) indicated 
that they were influenced by information on the container label, while 63 (32%) 
indicated that they were not. Among all the factors that were assessed, 
participants indicated that they are influenced by brand name (n = 132), 
ingredients (n = 129), recommended dosage and directions for use (n = 132) 
and claims (n = 127).  
 
Table 5.2 demonstrates the difference between the amount of silymarin as 
declared on the label and the amount detected using LC-MS for analysis in this 
study.  
 
The silymarin contents varied between the different brands of commercially 
available extracts, ranging from 5,1 mg in sample 6 to 62,7 mg in sample 3 
(Table 5.2). The ratios of the individual flavonolignans were also different 
(Table 4.1), which is in line with previously done studies on Silybum marianum 














Product 1  24 5,13 21,38 
Product 2  NP 40,6 NA 
Product 3 200 62,7 31,35 
Product 4  160 45,6 28,51 
Product 5   112 35,3 31,52 
Product 6 NP 5,1 NA 
NA- Not applicable; NP – not provided 
 
The great amount of variability seen between products can be attributed to the 
many factors known to affect the complex composition of milk thistle (Fenclova 
et al., 2019). These factors include chemotypic and genotypic variations; 
variations in growing conditions; harvesting, drying or storage of the plant 
matter used; differences in geological origin; as well as in the methods of 
extraction (Eklund et al., 2009; Lee et al., 2007; Petrásková et al., 2020; Poppe 
& Petersen, 2016). The maintenance of GMP is vital if quality herbal medicines 
are desired (WHO, 2011). 
 
Poppe & Peterson (2016) investigated the variation in the flavonolignan 
composition of the fruits from different Silybum marianum chemotypes and 
suspension cultures derived thereoff. Their results demonstrated the 
composition of the silymarin mixture depends on the Silybum marianum 
chemotype.  
 
The results of the LC-MS investigation confirmed that all the products tested 
did contain the flavonolignans typically observed in milk thistle extract. 
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However, the total silymarin content was much less than the amount declared 
on the labels for all samples analysed. None of the samples were found to have 
the exact quantity of silymarin as declared on the label. The percentage of 
actual silymarin tested compared to the declared silymarin content for sample 
5 was the closest to the declared value with 31,52% of the amount of silymarin 
declared by the manufacturer and stated on the product label, closely followed 
by sample 3 (31,35%), and then sample 4 (28,51%) and sample 1 (21,28%). 
The silymarin percentages could not be calculated for samples 2 and 6 as they 
were not stipulated on the product labels.  
 
In a study done in the United States of America (USA) by Eklund et al. (2009), 
six different commercial Silybum marianum extracts were analysed using high-
performance liquid chromatography (HPLC) to assess their concentrations of 
flavonolignans. All the supplements tested consistently demonstrated lower 
amounts of total flavonolignans when compared to the concentrations declared 
on the bottle.  
 
A study conducted by Fenclova et al. (2019) on 26 milk thistle supplements 
available in the Czech Republic and the USA found large differences in the 
silymarin content between the different preparations. There were also 
differences between the findings of their analyses of the samples and the 
information provided by the manufacturers. The study of Fenclova et al. (2019) 
also found substantial inter-batch differences in silymarin content. 
 
In this study, there were only small inconsistencies and inter-batch differences 
in the silymarin content of different capsules in the same sample (Table 4.2).  
 
The four main flavonolignan isomers in silymarin are silibinin, isosilibinin, 
silichristin and silidianin, but the most prevalent and biologically active of these 
is silibinin (also called silybin) (Chambers et al., 2017; Gillessen & Schmidt, 
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2020). Approximately 50–60% of the silymarin complex is silibinin, with the 
other flavonolignan isomers comprising about 35%: silichristin (~ 20%), 
silidianin (~ 10%) and isosilibinin (~ 5%) (Chambers et al., 2017; Csupor et al., 
2016; Sabir et al., 2014). Due to its relative abundance and ease of extraction, 
silybin is the constituent most often used to assess quality and according to the 
European Pharmacopoeia should range between 50% and 60% of total 
silymarin (Abenavoli et al., 2018). As seen in Table 4.3 the percentage of silybin 
present in each capsule varies from 39,12% in sample 5 to 57,6% in sample 2.  
 
However, the use of silybin as a percentage of total silymarin may create a 
false impression of quality or potency of a herbal preparation or extract. The 
use of the silybin percentages to compare the quality of each sample puts 
sample 6 (50,76% silybin) in fourth place, and sample 5 is ranked sixth with the 
lowest silybin percentage (39,12%). However, sample 6 has the lowest amount 
of total flavonolignan of all six analysed samples with 5,1 mg silymarin per 
capsule, while sample 5 ranks fourth with 35,3 mg silymarin per capsule. 
 
The great variation in the declared values versus the detected values of 
flavonolignan in the six products tested in this study strongly indicates the need 
for improved quality control regulations with regards to constituent composition 
as well as the use of sensitive and specific analytical analyses of the 
standardised extracts (Fenclova et al., 2019; Zhang et al., 2011). This may 
assist in guaranteeing that end-users are taking the required flavonolignan 
dosage to receive the therapeutic benefits from the milk thistle supplement.  
 
There are many available dosage forms of milk thistle including capsules, 
tablets, tinctures and intravenous solutions. The adult therapeutic dosage is 
420 mg/day for 6-8 weeks of extract standardised to 70-80% silymarin (294-
336 mg silymarin) (Abenavoli et al., 2018; Karimi et al., 2011). A daily 
maintenance dose is 280 mg/day of a standardised extract with 70-80% 
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silymarin providing 196-224 mg silymarin (Karimi et al., 2011). At the 
recommended maintenance dose of about ±200 mg silymarin per day, most of 
the samples all fall short. 
 
The lack of good quality products and standardisation impacts the results of 
clinical trials. Poor quality Silybum marianum extracts may be the reason for 
inconsistent clinical observations and unproven efficacy of milk thistle in many 
studies. The increase in cases of herbal drug-induced liver injury may also be 
due to the inaccurate declarations of the composition of each extract and either 
inadvertent or deliberate adulteration of these products (Fenclova et al., 2019). 
Inaccurate declarations of known substances yields a concern as to what 
unknown substances exist. 
 
The cost per mg of silymarin was determined using the price per capsule for 
each sample. Through this analysis based on price per milligram of silymarin, 
samples 3 and 4 were the most cost-efficient products and sample 1 was the 
least. It appears that cost is not indicative of the quality or quantity of the 
product. This finding is further supported by the results shown in Table 5.3 
below.  
 
Table 5.3: Cost per mg of total flavonolignan 














Sample 1 104,00 30 3,47 5,13 0,68 
Sample 2 299,00 100 2,99 40,6 0,07 
Sample 3 161,95 90 1,80 62,7 0,03 
Sample 4 76,95 60 1,28 45,6 0,03 
Sample 5 255,00 60 4,25 35,3 0,12 
Sample 6 106,95 60 1,78 5,1 0,35 
ZAR- South African Rand; mg – milligram  
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As seen in Table 5.4, sample 4 is the cheapest product per 60-capsule 
container, it is the cheapest per capsule, has the second highest silymarin 
content per capsule, and it is the cheapest overall for getting to a 200 mg 
therapeutic dose.  
 






























































































104,00 30 3,47 5,13 39 135,33 
Sample 
2 
299,00 100 2,99 40,6 5 14,95 
Sample 
3 
161,95 90 1,80 62,7 3 5,40 
Sample 
4 
76,95 60 1,28 45,6 4 5,12 
Sample 
5 
255,00 60 4,25 35,3 6 25,2 
Sample 
6 
106,95 60 1,78 5,1 39 69,42 
ZAR – South African rand, cap – capsule, caps – capsules, mg – milligram, no. – number   
 
Sample 3 is third most expensive on shelf, second cheapest per capsule, 
highest silymarin content per capsule, and second cheapest overall for 200 mg 
dose. Sample 1 is the second cheapest on the shelf, most expensive per 
capsule with the second lowest silymarin content per capsule and is therefore, 
the least cost effective for a maintenance dose. Sample 5 is the second most 
expensive per unit and most expensive per capsule, but with a moderate 
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concentration of silymarin per capsule, it is the third most expensive product 
for a maintenance dose. 
 
When it comes to herbal medicines, it is suggested that a more expensive 
product may be indicative of a better quality (Nevein et al., 2014), however this 
study demonstrates otherwise. For example, samples 3 and 6 of similar cost 
per capsule have substantially different concentrations of silymarin per 
capsule. 
 
5.3  GC-MS Analysis for Pesticide Residues 
Pesticides are widely used in the agricultural production of herbal drug 
materials for the prevention and control pests, moulds, diseases, and other 
plant pathogens in order to decrease or eliminate the potential loss of crops 
and to preserve the product quality (Chen et al., 2016; Nevein et al., 2014). The 
milk thistle plant is vulnerable to many pests and diseases (Karkanis et al., 
2011).  
 
Since 1963 pesticide residues have been detected in herbal drug materials, 
with most reports being published in the last 20 years (Perez-Parada et al., 
2011). Several studies have described the contamination of Silybum marianum 
supplements with pesticide residues (Chen et al., 2016; Fenclova et al., 2019; 
Nevein et al., 2014). These residues have become a significant source of 
contamination therefore, the WHO and other regulatory authorities have 
established and defined maximum residue levels (MRLs) for these 
contaminants (Fenclova et al., 2019; Perez-Parada et al., 2011; Zhang et al., 
2011).  
 
A study conducted by Fenclova et al (2019) assessed the composition and 
safety of 26 commercially available milk thistle supplements in the Czech 
Republic and the USA. The samples were analysed for contamination by 
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mycotoxins, plant alkaloids, pesticide residues and microbe content. Of the 323 
pesticide compounds investigated, only five were detected and quantified. To 
assess the severity of contamination by these pesticide residues, the detected 
concentrations were compared with the European Union (EU) regulatory MRLs 
and these maximal limits were exceeded in three of the 26 milk thistle products.  
 
The residues of six different pesticides were detected by HPLC analysis in an 
Egyptian traditional herbal combination supplement that includes silymarin, 
however all pesticides were detected within the limits established by regulatory 
authorities (Nevein et al., 2014). 
 
Chen et al (2016) analysed nine commercially available tea samples and 23 
ginseng samples using GC-MS. The results revealed 36 pesticides were 
detected in the nine tea samples at concentrations of 2−3500 μg/kg and 61 
pesticides were detected in the 23 ginseng samples at concentrations of 
1−12500 μg/kg. The pesticides found in these tea samples were those also 
present in the MRL lists established by EU and Japan for tea. Ten detected 
pesticides in the samples with concentrations over the EU MRL were 
acetamiprid, α-,β-,and δ-BHC, buprofenzin, clomazone, diphenylamine, 
monocrotophos, pyridaben and triazophos. 
 
Organochloride pesticides (OCPs) are the most frequently reported pesticide 
residue detected in herbal medicines (Zhang et al., 2011). OCPs are very 
stable compounds, lending to their persistence in the environment for many 
years after initial use (Zikankuba et al., 2019). The main adverse health effects 
resulting from the chronic ingestion of OCPs are directly associated with the 
development of chronic illness and a variety of different cancers (Nevein et al., 
2014). For this reason, as well as their persistence in the environment, their 
use has been banned internationally for over 30 years (Perez-Parada et al., 




The six commercial milk thistle supplements were analysed by GC-MS for the 
residues of 15 organochlorine pesticides namely Aldrin, α-BHC, β-BHC, γ-BHC 
(Lindane), cis-Chlordane, trans-Chlordane, 4,4'-DDD, 4,4'-DDE, Dieldrin, 
Chloroanthil, Chlorobenzilate, Endrin, Heptachlor, Hexachlorobenzene and 
Hexachloropentadiene. The results of this investigation demonstrated the 
absence of all target OCPs.  
 
This result indicates that there were no OCPs used in the manufacture of these 
milk thistle products and that these pesticides were never used or no longer 
persist in the soil and environment in which the herbal drug material was grown 
(Zhang et al., 2011; Zikankuba et al., 2019).  
 
5.4  ICP-MS Analysis for Heavy Metals and Trace Elements  
Herbal products have been found to have evidence of heavy metal 
contamination in several countries of Africa, South America and Asia (Dghaim 
et al., 2015; Zhang et al., 2012). In South Africa, metal poisoning resulting from 
the use of traditional medicines is not uncommon (Okem et al., 2014).  
 
In a study done by Annan et al. (2013) assessing the heavy metal content of 
some medicinal plants sampled from different locations in Ghana using atomic 
absorption spectrophotometry, it was concluded that the same species of 
medicinal plants, growing in different locations and environments, accumulate 
different levels of heavy metals. 
 
The levels of essential elements in different medicinal plants were analysed 
using ICP-MS by Brima (2018). This study concluded that the calculated 
intakes of essential elements for all the assessed medicinal plants did not 
exceed the daily intake set by the WHO and therefore, may be useful sources 




The need for an in-depth investigation into the safety, regulation and 
authenticity of herbal medicinal material sold in South Africa was highlighted in 
a study done by Okem et al. (2014) who observed high levels of both iron and 
aluminium in various plant materials analysed by ICP-MS.  
 
A multivariate analysis of elemental impurities in 19 species of herbs consumed 
in Yunnan, China by inductively coupled plasma-atomic emission spectrometry 
(ICP-AES) showed that the elemental concentrations in medicinal plants varied 
depending on the species, origin environment, and harvest period as well as 
other factors, can influence the elemental concentrations. Furthermore, 
medicinal herbs may be easily contaminated during growing and processing 
and therefore, it is important to shed more light on good quality control practices 
for medicinal herbs (Dong et al., 2017) 
 
Table 5.5 demonstrates the concentrations of heavy metal and trace element 
impurities per micrograms (ug) per gram as well as the amount of micrograms 














Table 5.5: The average concentrations of heavy metal and trace elements 
detected (ug/g and ug/cap) 
Metal /  
element  




3 0,61 1,39 45,07 6,03 
157,7
4 0,00 0,26 
ug/cap 48,40 0,15 0,35 11,44 1,53 40,05 0,00 0,07 
SAMPLE 
2 
ug/g 11,39 0,23 0,30 0,13 0,57 2,44 0,00 0,03 
ug/cap 4,98 0,09 0,13 0,06 0,25 1,07 0,00 0,01 
SAMPLE 
3 
ug/g 6,32 0,17 0,16 0,00 0,34 3,93 0,03 1,17 




3 4,55 14,32 39,19 20,95 
118,6
1 0,05 0,85 




88 17,77 7,29 21,88 51,67 
2162,
84 0,25 1,24 
ug/cap 628,5
4 10,28 4,22 12,65 29,88 
1250,




7 5,72 22,86 60,29 48,49 
235,2
1 0,27 1,41 
ug/cap 172,3
0 2,95 11,77 31,05 24,97 
121,1
3 0,14 0,73 
Al – aluminium; Cd – cadmium; Cu – copper; Fe – iron; Pb – lead; Mn – manganese; Ni – 
nickel; Zn – zinc; ug/g – microgram per gram; ug/cap – microgram per capsule 
 
5.4.1 Iron 
Studies show that individuals present with early symptoms of gastrointestinal 
toxicity from ingesting more than 20 ug/g iron, while “moderate” intoxication 





The average iron content of the six analysed milk thistle products was in the 
range of 6,32 ug/g or 2,72 ug/capsule (sample 3) to 1 086,88 ug/g or 628,54 
ug/capsule (sample 5). 
 
As seen in Table 5.6, samples 2 and 3 had levels of iron that were within all the 
guideline safety recommendations. When observing the levels of iron in the 
therapeutic doses, sample 3 is the only sample that remains within the 
guideline concentration levels with a concentration of 8,16 ug/g. Sample 2 had 
iron levels within safety ranges for one capsule (4,98 ug/cap), but at five 
capsules per day for its therapeutic dosage (24,9 ug/g), it was over the 
recommended safety ranges. Sample 6 has the second highest amount of iron 
contamination per capsule (172, 30 ug/g) but the highest amount of 
contamination in the therapeutic dose of 39 capsules (6731,4 ug/g). This 
means that at the dosage recommended on the label, four of the products had 
iron levels that pose a high risk for lethal human toxicity with unsafe levels of 
iron above 60 ug/g.  
 
Table 5.6: Iron (Fe) concentration per capsule, maximum daily dose (in number 
of capsules, as per product label) and therapeutic dose (number of capsules to 
get to 200mg silymarin per day) 
Sample 
No. 















1 48,4 2 capsules  96,8 39 
capsules 
1891,5 
2 4,98 1 capsule 4,98 5 capsules 24,90 
3 2,72 3 capsules 8,16 3 capsules 8,16 
4 87,39 1-3 
capsules 
87,39-262,17 4 capsules 349,56 




6 capsules 3771,24 
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6 172,30 2 capsules 344,60 39 
capsules 
6731,4 
Ave – average; Fe – iron; ug/g – microgram per gram; mg – milligram  
  
5.4.2 Nickel 
In the six standardised Silybum marianum extracts the levels of nickel present 
ranged from 0,17 ug/g or 0,07 ug/capsule in sample 3 to 17,77 ug/g or 10,28 
ug/capsule in sample 5. The WHO has classified nickel as a class 2A toxic 
element and has established a permissible limit of 2 ug/g in herbal medicines 
with a daily dosage of fewer than 10 grams per day. Therefore, the results show 
that three of the products analysed contain unsafe levels of nickel which may 
result in toxic effects on human health. Though uncommon due to its low 
absorption rates in the human body (Umar et al., 2016), exposure to high 
amounts of nickel may result in a variety of pathological effects, adversely 




As seen in Table 4.5, the results of the present study demonstrated a range of 
0,16 ug/g or 0,07 ug/capsule (sample 3) to 22,86 ug/g or 11,77 ug/capsule 
(sample 6) across the samples for the presence of copper. The concentrations 
of the class 3 toxic element copper, were therefore below the regulatory limit of 
30 ug/g as set by the Food and Agriculture Organization (FAO) and WHO, and 




The results of the ICP-MS analysis of the six milk thistle products showed a 
range of 0 ug/g (sample 3) to 60,29 ug/g or 31,05 ug/capsule (sample 6). The 
high levels of zinc in sample 6 may cause potential harm to human health as 
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symptoms of zinc toxicity occur as a result of excessive intake at levels above 
the 50 ug/g as determined by the WHO. 
 
5.4.5 Manganese 
The average concentration of manganese in the studied samples ranged 
between 0,34 ug/g or 0,15 ug/capsule in sample 3 and 51,67 ug/g or 29,88 
ug/capsule in sample 5. The FAO/WHO have not set permissible intake levels 
for this element however, overexposure to this element may cause manganism, 
a neurodegenerative disorder that is due to the susceptibility of the brain 
towards excess of manganese (Rasdi et al., 2013).  
 
5.4.6 Aluminium 
The present study demonstrated results with great variation in the average 
concentration of aluminium detected in each sample. The FAO/WHO have not 
set permissible limits for the intake of aluminium, but the daily allowance for 
ingestion in humans has been estimated to range between 10 mg and 50 mg 
(Okem et al., 2014). The recommended daily dosage for sample 5 is three 
capsules per day. This would result in a total daily intake of 3752,31 ug and 
therefore, may be of concern due its’ prevalence in the environment and its 
ability to accumulate in the human body (Kfle et al., 2020).   
 
5.4.7 Cadmium 
According to the results of the present study the non-essential element 
cadmium was found in four of the samples analysed, ranging from 0,03 ug/g or 
0,01 ug/capsule in sample 3 to 0,27 ug/g or 0,14 ug/capsule in sample 6. The 
FAO/WHO have set the permissible intake levels for cadmium at 0,5 ug/g for 
herbal drug products with a daily intake of less than 10mg and classified it as 
a class 1 toxic elemental impurity. Because of its ability to accumulate in the 
tissues over time as well as its link to the development of cancers, the presence 





All the samples investigated in this study had detectable levels of the non-
essential trace element lead. Four of these samples were measured above the 
recommended intake level of 0,5 ug/g as set by the WHO/FAO who also 
classified lead as a class 1 toxic element. The lowest concentration of lead was 
seen in sample 2 (0,02 ug/g or 0,01 ug/capsule) and the highest was seen in 
sample 6 (1,41 ug/g or 0,73 ug/capsule). These levels are of great health 
concern and the repeated exposure as seen in supplementation may result in 
the bioaccumulation of lead in the human body and therefore, negative health 
effects for the consumer. 
 
5.5  Mass of the Sample Capsules 
Table 5.6 compares the actual mass of the contents of the products tested to 
the mass declared on the label (Table 5.1). The samples had a consistent mass 
for the whole capsule, as well as the mass of the contents of the capsules for 
all samples, but there were discrepancies between what was stated on the 
product labels and the content mass obtained in this study.  
 
As seen in Table 5.7, the mass of sample 1 with a capsule content mass of 
253,9 mg was 76,1 mg less than declared on label (330 mg). All the other 
samples had a higher mass on contents than the silymarin powder mass 
declared on the label. These variations may be attributed to the consistency of 
the plant material and its flowing properties, the type and speed of the 
machines used to fill the capsules, defects in machinery that result in 
misalignment of the upper and lower capsule segments as well as possible 
additions to the contents, for example, inert fillers, anti-caking agents and other 





Table 5.7: Mass of capsule contents (mg) versus mass of silymarin powder 


















Sample 1a 346,7 253,9 
330 -76,1 
Sample 1b 346,7 253,9 
Sample 1c 346,7 253,9 
Sample 1 
ave 346,7 253,9  
Sample 2a 536,2 436,8 
200 +236,8 
Sample 2b 536,2 436,8 
Sample 2c 536,2 436,8 
Sample 2 
ave 536,2 436,8 
Sample 3a 526,2 430,9 
250 +180,9 
Sample 3b 526,2 430,9 
Sample 3c 526,2 430,9 
Sample 3 
ave 526,2 430,9 
Sample 4a 518,3 419,5 
400 +19,5 
Sample 4b 518,3 419,5 
Sample 4c 518,3 419,5 
Sample 4 
ave 518,3 419,5 
Sample 5a 701,4 578,3 
300 +278,3 
Sample 5b 701,4 578,3 
Sample 5c 701,4 578,3 
Sample 5 
ave 701,4 578,3 
Sample 6a 612,6 515 
400 +115 
Sample 6b 612,6 515 
Sample 6c 612,6 515 
Sample 6 
ave 612,6 515 
mg – milligram, ave- average 
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5.6  Conclusion 
Table 5.8 contains an overall scoring and rating for the quality of all six milk 
thistle products tested in this study as suggested by the information gathered 
in the analyses. The researcher rated the samples according to all the elements 
assessed in this study: i) chromatographic fingerprint; ii) levels of 
flavonolignans (particularly silymarin); iii) comparison of  label information 
regarding silymarin content and test results;  iv) the presence or absence  of 
pesticides; v) the presence or absence of heavy metals and trace elements, 
particularly at potentially toxic levels; vi) mass of the capsule contents; and vii) 
value for money or cost-effectiveness in getting to a therapeutic dose. Any 
samples deemed uncompliant cannot be given an overall score as it would 




Table 5.8: An overall scoring and rating for the quality of all six milk thistle products tested in this study as 
suggested by the information gathered in the analyses. 
 
> - more than; ≥ - equal to or greater than 





ph fingerprint  
All peaks: 1 
Missing / 




















































expensive: 0  
Overall 
score 
1 1 0 1 1 1 0 0 NC = 0 
2 1 0 3 1 1 1 1 NC = 0 
3 1 0 5 1 -1 1 2 NC = 0 
4 1 0 4 1 -2 1 2 NC = 0 
5 1 0 2 1 -3 1 1 NC = 0 




CONCLUSION AND RECOMMENDATIONS 
 
6.1  Conclusion 
The results of the LC-MS analysis of flavonolignans showed that all the 
analysed samples had the necessary peaks associated with the presence of 
silymarin. No extra or missing peaks were noted. However, none of the 
samples had the quantity of silymarin as declared on their labels and ranged 
from 68,65- 78,62% below the declared silymarin content. The GC-MS analysis 
for organochloride pesticides did not detect any residues that indicated 
contamination.   
 
Samples 1 and 2 were the only samples that did not have concentrations above 
permissible limits for heavy and trace elemental impurities as determined by 
ICP-MS analysis. Levels of lead were above these limits in four samples 
(sample 3, 4, 5 and 6), while the level of nickel was above these limits in three 
samples (sample 4, 5 and 6) and cadmium in sample 5, representing a potential 
health concern to users.  
 
Apart from sample 1, the mass of the contents of the capsules was in line with 
what was declared on the labels.  
 
Based on all the elements assessed in this study, namely flavonolignan 
(particularly silymarin) content, label information, capsule content mass, the 
presence or absence of pesticides, heavy metals and trace elements, and 
value for money, none of the products meet regulatory requirements and 
samples 4-6 pose potential health risks to consumers.  
 
Samples 3 and 4 were the most cost effective and had the highest levels of 
silymarin per capsule. Samples 5 and 6 had the third lowest and lowest levels 
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of silymarin, the highest and second highest levels of contamination, and were 
rated as medium and least cost-effective respectively.  
 
The results of this study have been reported to SAHPRA.  
  
The limitations of this study include the small number of different commercially 
available brands used and therefore, the number of samples analysed. Further 
detailed evaluations could better our understanding of the quality of these 
products, for example a visual analysis of the contents of the capsule, the 
determination of other pesticide residues including organophosphates and 
nitrogen-containing pesticides, and the determination of many other common 
toxic elemental impurities and microbiological contaminant such as 
mycotoxins. 
 
6.2  Recommendations 
• Further testing of additional parameters (as laid out in the limitations) of 
these and other Silybum marianum L. Gaertn. products would better our 
understanding of the overall quality of herbal medicines.  
• A larger sample group including more product brands would also provide 
a greater overview of the quality of Silybum marianum L. Gaertn. 
products and extracts in South Africa and by extension Southern Africa.  
• Future studies should be extended to neighbouring countries 
considering the numerous trade activities happening within the Southern 
African region.  
• Similar studies can also be conducted on different single-herb products, 
such as those made from Echinacea species, Hypericum perforatum (St 
John’s wort), and other herbs available as off-the-shelf preparations to 
consumers.  
• Based on the results of the study, the evaluation of these products by 
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APPENDIX C: Method Validation and Calibration for LC-MS Analysis 
 
The calibration concentrations used for the development of the calibration 
curve of the reference standard Milk Thistle dry extract from European 
Pharmacopeia (Y0001687) used in LC-MS analysis 
31.25 ppm MT MilkThistle 1:A,7 2 Standard 8.21875 
62.5 ppm MT MilkThistle 1:A,8 2 Standard 16.4375 
125 ppm MT MilkThistle 1:B,1 2 Standard 32.875 
250 ppm MT MilkThistle 1:B,2 2 Standard 65.75 
 500 ppm MT MilkThistle 1:B,3 2 Standard 131.5 
1000 ppm MT MilkThistle 1:B,4 2 Standard 263 
 
The calibration curve of the reference standard Milk Thistle dry extract from 






























APPENDIX D: Certificate of Analysis, Conditions and Calibrations of Certified 




































Hexachloropentadiene 9.62 Positive 2 270 235 14 5 
Hexachloropentadiene 9.62 Positive 2 272 237 16 5 
Chloroneb 11.88 Positive 2 191 113 13 5 
Chloroneb 11.88 Positive 2 191 141 10 5 
Chloroneb 11.88 Positive 2 206 191 10 5 
Chloroneb 11.88 Positive 2 208 193 10 5 
alpha-BHC  14.27 Positive 2 181 109 28 5 
alpha-BHC  14.27 Positive 2 181 145 14 5 
alpha-BHC  14.27 Positive 2 183 147 26 5 
alpha-BHC  14.27 Positive 2 217 181 8 5 
alpha-BHC  14.27 Positive 2 219 183 8 5 
HCB 14.43 Positive 2 249 214 14 5 
HCB 14.43 Positive 2 284 214 30 5 
HCB 14.43 Positive 2 284 249 18 5 
beta BHC  14.82 Positive 2 181 109 28 5 
beta BHC  14.82 Positive 2 181 145 14 5 
beta BHC  14.82 Positive 2 183 147 26 5 
beta BHC  14.82 Positive 2 217 181 8 5 
beta BHC  14.82 Positive 2 219 183 8 5 
gamma BHC (Lindane) 15.08 Positive 2 181 109 28 5 
gamma BHC (Lindane) 15.08 Positive 2 181 145 14 5 
gamma BHC (Lindane) 15.08 Positive 2 183 147 26 5 
gamma BHC (Lindane) 15.08 Positive 2 217 181 8 5 
gamma BHC (Lindane) 15.08 Positive 2 219 183 8 5 
93 
 
Chlorothalonil 15.48 Positive 2 264 168 23 5 
Chlorothalonil 15.48 Positive 2 266 133 40 5 
Chlorothalonil 15.48 Positive 2 266 170 23 5 
delta BHC 15.83 Positive 2 181 109 22 5 
delta BHC 15.83 Positive 2 181 145 12 5 
delta BHC 15.83 Positive 2 183 147 24 5 
delta BHC 15.83 Positive 2 217 181 10 5 
delta BHC 15.83 Positive 2 219 183 10 5 
Acetochlor 16.81 Positive 2 174 146 12 5 
Acetochlor 16.81 Positive 2 223 132 20 5 
Acetochlor 16.81 Positive 2 223 146 10 5 
Acetochlor 16.81 Positive 2 223 147 10 5 
Acetochlor 16.81 Positive 2 223 174 10 5 
Heptachlor 17.46 Positive 2 100 65 12 5 
Heptachlor 17.46 Positive 2 270 235 13 5 
Heptachlor 17.46 Positive 2 272 237 13 5 
Aldrin 19.04 Positive 2 263 191 30 5 
Aldrin 19.04 Positive 2 263 193 30 5 
Aldrin 19.04 Positive 2 329 186 38 5 
Aldrin 19.04 Positive 2 329 220 28 5 
Heptachlor Epoxide 20.37 Positive 2 263 193 29 5 
Heptachlor Epoxide 20.37 Positive 2 351 261 11 5 
Heptachlor Epoxide 20.37 Positive 2 353 263 13 5 
cis-Chlordane 21.03 Positive 2 272 237 12 5 
cis-Chlordane 21.03 Positive 2 375 266 21 5 
cis-Chlordane 21.03 Positive 2 377 268 19 5 
2,4-DDE 21.15 Positive 2 246 176 32 5 
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2,4-DDE 21.15 Positive 2 316 246 15 5 
2,4-DDE 21.15 Positive 2 318 176 56 5 
trans-Chlordane 21.35 Positive 2 272 237 13 5 
trans-Chlordane 21.35 Positive 2 373 264 18 5 
trans-Chlordane 21.35 Positive 2 375 266 18 5 
trans-Nonachlor 21.43 Positive 2 409 263 25 5 
trans-Nonachlor 21.43 Positive 2 409 300 20 5 
trans-Nonachlor 21.43 Positive 2 409 302 22 5 
4,4-DDE_C13 (ISTD) 21.82 Positive 2 328 258 20 5 
4,4-DDE_C13 (ISTD) 21.82 Positive 2 330 260 20 5 
4,4-DDE 21.84 Positive 2 246 176 28 5 
4,4-DDE 21.84 Positive 2 316 246 20 5 
4,4-DDE 21.84 Positive 2 318 248 22 5 
Dieldrin 21.89 Positive 2 263 191 34 5 
Dieldrin 21.89 Positive 2 263 193 28 5 
Dieldrin 21.89 Positive 2 277 241 12 5 
Dieldrin 21.89 Positive 2 279 243 12 5 
2,4-DDD 21.95 Positive 2 235 165 30 5 
2,4-DDD 21.95 Positive 2 235 165 22 5 
2,4-DDD 21.95 Positive 2 235 199 14 5 
2,4-DDD 21.95 Positive 2 237 165 22 5 
Endrin 22.29 Positive 2 245 173 25 5 
Endrin 22.29 Positive 2 263 193 30 5 
Endrin 22.29 Positive 2 279 243 8 5 
Chlorobenzilate 22.41 Positive 2 139 75 30 5 
Chlorobenzilate 22.41 Positive 2 139 111 12 5 
Chlorobenzilate 22.41 Positive 2 251 111 10 5 
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Chlorobenzilate 22.41 Positive 2 251 111 32 5 
Chlorobenzilate 22.41 Positive 2 251 139 10 5 
Chlorobenzilate 22.41 Positive 2 251 139 14 5 
Chlorobenzilate 22.41 Positive 2 253 141 10 5 
4,4-DDD 22.57 Positive 2 235 165 24 5 
4,4-DDD 22.57 Positive 2 235 199 20 5 
4,4-DDD 22.57 Positive 2 235 199 12 5 
4,4-DDD 22.57 Positive 2 237 165 22 5 
Endrin Aldehyde 22.71 Positive 2 250 142 40 5 
Endrin Aldehyde 22.71 Positive 2 250 215 35 5 
Endosulfan Sulfate 23.08 Positive 2 241 206 8 5 
Endosulfan Sulfate 23.08 Positive 2 272 237 10 5 
Endosulfan Sulfate 23.08 Positive 2 274 239 12 5 
4,4-DDT_C13 (ISTD) 23.15 Positive 2 247 177 20 5 
4,4-DDT_C13 (ISTD) 23.15 Positive 2 249 177 20 5 
4,4-DDT 23.17 Positive 2 235 165 30 5 
4,4-DDT 23.17 Positive 2 235 165 21 5 
4,4-DDT 23.17 Positive 2 235 199 30 5 
4,4-DDT 23.17 Positive 2 235 199 16 5 
4,4-DDT 23.17 Positive 2 237 165 30 5 
4,4-DDT 23.17 Positive 2 237 165 22 5 
Endrin Ketone 23.85 Positive 2 315 279 8 5 
Endrin Ketone 23.85 Positive 2 317 101 21 5 
Endrin Ketone 23.85 Positive 2 317 245 20 5 
Endrin Ketone 23.85 Positive 2 317 281 8 5 
Methoxychlor 24.04 Positive 2 227 115 50 5 
Methoxychlor 24.04 Positive 2 227 141 33 5 
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Methoxychlor 24.04 Positive 2 227 169 25 5 
cis-Permethrin 25.82 Positive 2 163 127 6 5 
cis-Permethrin 25.82 Positive 2 183 153 12 5 
cis-Permethrin 25.82 Positive 2 183 168 10 5 
trans-Permethrin 25.98 Positive 2 163 91 13 5 
trans-Permethrin 25.98 Positive 2 163 127 6 5 
trans-Permethrin 25.98 Positive 2 183 153 14 5 
 
The concentrations (ng/L) used for the calibration curve of the standard 
reference material for the GC-MS analysis 
 
Level 1  Level 2 Level 3 Level 4 Level 5 Level 6 












































































































The calibration curve of the γ-BHC (Lindane) compound present in the standard 













The calibration curve of the Hexachlorobenzene compound present in the 





The calibration curve of the Aldrin compound present in the standard reference 
material for the GC-MS analysis 
 
The calibration curve of the Heptachlor compound present in the standard 





The calibration curve of the trans-Chlordane compound present in the standard 
reference material for the GC-MS analysis 
 
The calibration curve of the Chlorobenzilate compound present in the standard 





The calibration curve of the Hexachloropentadiene compound present in the 
standard reference material for the GC-MS analysis 
 
The calibration curve of the cis-Chlordane compound present in the standard 
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used in the ICP-MS Analysis 
APPENDIX F: Method Validation and Calibration for ICP-MS Analysis 
 
The calibration concentrations used for the development of the calibration 
curve of the certified reference material used in ICP-MS analysis 





























































































APPENDIX I: Results of LC-MS Analysis 
 





















5152 1748 6917 13119 3237 11509 4140 42585 
Sampl
e 1 
4299 1777 7840 13217 2600 10610 3745 41488 
Sampl
e 1 
5130 1895 7105 12773 2766 11326 2650 40880 
Sampl
e 2 
7092 2736 15617 22569 2320 14294 4285 66594 
Sampl
e 2 
7380 1931 15425 22910 2222 14179 4190 66015 
Sampl
e 2 
7282 2641 15440 22870 2226 14234 4258 66724 
Sampl
e 3 
5585 2213 10989 17959 4460 12342 3210 52298 
Sampl
e 3 
5497 2025 10014 17570 3774 12448 3514 51068 
Sampl
e 3 
5178 1987 10659 17549 2712 12229 3110 50712 
Sampl
e 4 
4222 1722 7002 12199 2743 9757 3454 38356 
Sampl
e 4 
4107 1542 6836 11986 2226 9362 2662 36496 
Sampl
e 4 
3897 1427 7108 11909 2705 9553 3097 36991 
Sampl
e 5 
4094 1700 3346 7803 2485 9904 2884 29731 
Sampl
e 5 
4150 1456 3544 8008 2618 9988 2001 29147 
Sampl
e 5 
3806 1525 3453 7944 2459 9509 1587 27825 
Sampl
e 6 
4299 1777 7840 13217 2600 10610 3745 41488 
Sampl
e 6 
4313 1767 8065 12827 2067 11123 3261 41355 
Sampl
e 6 








Results expressed as the total silymarin relative to the standards, taking the 
























Sample 1 42585.191 5.2 10 5 0.3467 0.2539 20.50
Sample 1 42558.244 5.2 10 5 0.3467 0.2539 20.49
Sample 1 40880.315 5.0 10 5 0.3467 0.2539 19.68
Sample 2 66594.144 40.7 10 25 0.5362 0.4368 93.18
Sample 2 66014.675 40.3 10 25 0.5362 0.4368 92.37
Sample 2 66724.346 40.8 10 25 0.5362 0.4368 93.36
Sample 3 52298.16 63.9 10 50 0.5262 0.4309 148.36
Sample 3 51067.913 62.4 10 50 0.5262 0.4309 144.87
Sample 3 50712.272 62.0 10 50 0.5262 0.4309 143.86
Sample 4 38355.716 46.9 10 50 0.5183 0.4195 111.76
Sample 4 36495.655 44.6 10 50 0.5183 0.4195 106.34
Sample 4 36991.42 45.2 10 50 0.5183 0.4195 107.79
Sample 5 29731.434 36.3 10 50 0.7014 0.5783 62.84
Sample 5 29146.896 35.6 10 50 0.7014 0.5783 61.61
Sample 5 27825.329 34.0 10 50 0.7014 0.5783 58.81
Sample 6 41488.101 5.1 10 5 0.6126 0.515 9.85
Sample 6 41354.503 5.1 10 5 0.6126 0.515 9.82



































































































































S A M P L E  1 S A M P L E  2 S A M P L E  3 S A M P L E  4 S A M P L E  5 S A M P L E  6
Isosilibinin A Isosilibinin B Silibinin A Silibinin B Silichristin Silidianin
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APPENDIX K: A Graphical Representation for Average Concentration of 














Pb Cd Sr Zn Cu Ni Mn
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APPENDIX L: Plagiarism Report 
 
